



Docket No.: HO-P01925US1  
(PATENT)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of:  
Martin M. Matzuk et al.

Application No.: 09/830,810

Filed: October 28, 1999

Art Unit: 1653

For: OVARY-SPECIFIC GENES AND PROTEINS

Examiner: A. U. Desai

**APPEAL BRIEF**

MS Appeal Brief - Patents  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

As required under § 41.37(a), this brief is filed more than two months after the Notice of Appeal filed in this case on January 14, 2005, and is in furtherance of said Notice of Appeal.

The fees required under § 41.20(b)(2) are dealt with in the accompanying TRANSMITTAL OF APPEAL BRIEF.

06/16/2005 EFLORES 00000078 09830810  
02 FC:1402 500.00 OP

This brief contains items under the following headings as required by 37 C.F.R. § 41.37 and M.P.E.P. § 1206:

I.	REAL PARTY IN INTEREST.....	3
II.	RELATED APPEALS, INTERFERENCES, AND JUDICIAL PROCEEDINGS.....	3
III.	STATUS OF CLAIMS .....	3
A.	Total Number of Claims in Application .....	3
B.	Current Status of Claims.....	3
C.	Claims On Appeal .....	4
IV.	STATUS OF AMENDMENTS.....	4
V.	SUMMARY OF CLAIMED SUBJECT MATTER.....	4
VI.	GROUNDS OF OBJECTION TO BE REVIEWED ON APPEAL.....	4
VII.	ARGUMENT.....	5
A.	Substantial Evidence Required to Uphold the Examiner's Position .....	5
B.	Issue Under Claim Objection .....	5
C.	Issue Under Provisional Double Patenting.....	6
D.	Issue under 35 U.S.C. § 101 .....	6
1.	Claims 2 and 59 stand rejected .....	8
2.	Claims 5-7 stand rejected .....	8
3.	Claims 8-10 stand rejected .....	8
4.	Claims 58 and 60 stand rejected .....	9
E.	Issue Under 35 U.S.C. § 112, first paragraph.....	9
F.	Issue Under 35 U.S.C. § 112, second paragraph.....	9
VIII.	CLAIMS .....	9
IX.	EVIDENCE .....	10
X.	CONCLUSION .....	10
	APPENDIX A.....	12
	APPENDIX B.....	13

**I. REAL PARTY IN INTEREST**

The real party in interest for this appeal is Baylor College of Medicine, and its licensee, Wyeth.

**II. RELATED APPEALS, INTERFERENCES, AND JUDICIAL PROCEEDINGS**

There are no other appeals, interferences, or judicial proceedings which will directly affect or be directly affected by or have a bearing on the Board's decision in this appeal.

**III. STATUS OF CLAIMS**

**A. Total Number of Claims in Application**

Claims 1-57 were originally filed on April 27, 2001 in this case, which is the National Phase Application of PCT Application No. US99/25209 filed October 28, 1999 claiming priority to U.S. Provisional Application Serial No. 60/106,020, filed on October 28, 1998.

**B. Current Status of Claims**

In response to a Restriction Requirement dated October 2, 2003, Appellants elected Group II, claims 2-10 for continued prosecution.

Following an Office Action mailed April 21, 2004, a response was filed on July 21, 2004 canceling claims 1 and 11-57. Claims 58-61 were added.

A final Office Action was mailed on October 18, 2004 rejecting claims 2-10 and 58-61, and a response was filed December 20, 2004 canceling claim 4 and amending claim 2.

An Advisory Action was mailed on January 6, 2005 maintaining the rejection of claims 2, 3, and 58-61.

Appellants are submitting herewith an Amendment to cancel claims 58, 60 and 61 and amend claim 59, which was dependent upon claim 58.

**C. Claims On Appeal**

In view of the amendment submitted herewith, the claims on appeal are claims 2, 3, and 5-10 and 59.

**IV. STATUS OF AMENDMENTS**

Applicant filed an Amendment After Final Rejection on December 20, 2004. The Examiner responded to the Amendment After Final Rejection in an Advisory Action mailed January 6, 2005. In the Advisory Action, the Examiner indicated that Appellants' proposed amendments to claim 2 and 4 would be entered.

Accordingly, the claims enclosed herein as Appendix A do incorporate the amendments to claims 2 and 4, as indicated in the paper filed by Appellants on December 20, 2004.

Appellants are submitting herewith an Amendment to cancel claims 58, 60 and 61 and amend claim 59, which was dependent upon claim 58. The amendments place the case in better condition for appeal by reducing the issues.

**V. SUMMARY OF CLAIMED SUBJECT MATTER**

The present invention concerns ovary-specific genes. More specifically O1-180 was isolated from mammalian ovarian tissue (e.g., see page 23, lines 21-26). The polynucleotide sequence of the claimed invention is SEQ. ID. NO. 1 as shown in Figure 1. This sequence is involved in ovarian function, such as fertility as indicated throughout the entire specification, for example see page 3, lines 1-2, 5 and 9, page 7, lines 9-13, page 23, lines 11-16, page 30, lines 13-16. In addition to SEQ. ID. NO. 1, the invention also concerns fully complementary sequences to SEQ. ID. NO. 1 (e.g., see page 8, lines 24-27, page 11, lines 27-29 and page 12, lines 1-4). SEQ. ID. NO. 1 can be inserted to an expression vector, such as a plasmid or a viral vector, for recombinant expression using a host cell, such as a prokaryotic or eukaryotic cell (e.g., see page 13, lines 9-28).

**VI. GROUNDS OF OBJECTION TO BE REVIEWED ON APPEAL**

Claim Objection to Claim 60 as being a substantial duplicate of claim 58.

Claims 2, 3, and 58-61 were provisionally rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1 and 2 of co-pending application No. 10/475,502.

Claims 2, 3, 5-10 and 58-61 were rejected under 35 U.S.C. § 101 as allegedly lacking an specific or well-established utility.

Claims 2, 3, 5-10 and 58-61 were rejected under 35 U.S.C. § 112, first paragraph.

Claims 58-61 were rejected under 35 U.S.C. § 112, second paragraph.

## **VII. ARGUMENT**

### **A. Substantial Evidence Required to Uphold the Examiner's Position**

As an initial matter, Appellants note that findings of fact and conclusions of law by the U.S. Patent and Trademark Office must be made in accordance with the Administrative Procedure Act, 5 U.S.C. § 706(A), (E), 1994. *Dickinson v. Zurko*, 527 U.S. 150, 158 (1999). Moreover, the Federal Circuit has held that findings of fact by the Board of Patent Appeals and Interferences must be supported by “substantial evidence” within the record. *In re Gartside*, 203 F.3d 1305, 1315 (Fed. Cir. 2000). In *Gartside*, the Federal Circuit stated that “the ‘substantial evidence’ standard asks whether a reasonable fact finder could have arrived at the agency’s decision.” *Id.* at 1312.

Accordingly, it necessarily follows that an Examiner’s position on Appeal must be supported by “substantial evidence” within the record in order to be upheld by the Board of Patent Appeals and Interferences.

### **B. Issue Under Claim Objection**

Claim 60 is objected as being a substantial duplicate of claim 58. Without agreeing with the substance of this rejection, Appellants have concurrently submitted herewith an Amendment canceling claim 60. Thus, this objection is now moot and Appellants request that it be withdrawn.

**C. Issue Under Provisional Double Patenting**

Claims 2, 3 and 58-61 are provisionally rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1 and 2 of co-pending application No. 10/475,502. Appellants traverse.

Appellants request that this rejection be held in abeyance until the conflicting claims are in fact patented.

**D. Issue under 35 U.S.C. § 101**

Claims 2, 3, 5-10 and 58-61 were rejected under 35 U.S.C. § 101 as allegedly lacking an specific or well-established utility. Appellants traverse this rejection.

Under the utility guidelines, the initial burden is on the Patent Office to establish a *prima facie* case of utility, which requires sufficient evidentiary basis. According to MPEP 2107.02, where the asserted utility is not specific or substantial, a *prima facie* showing contains the following:

- 1) An explanation that clearly sets forth the reasoning used in concluding that the asserted utility for the claimed invention is neither both specific and substantial nor well-established;
- 2) Support for factual findings relied upon reaching this conclusion; and
- 3) An evaluation of all relevant evidence of record, including utilities taught in the closest prior art.

The specification provides several functions or activities concerning the claimed polynucleotides. For example, page 3, line 9, states that the claimed polynucleotides can relate to “infertility.” Page 16, lines 17-19, page, 23, lines 12-16, page 30, lines 13-22 clearly state that mice deficient in the claimed polynucleotide will have fertility alterations, i.e., be infertile. Appellants assert that the SEQ.ID.NO. 1, the claimed polynucleotide of independent claim 1, is a mouse sequence, in which the specification clearly indicated that mice deficient in this sequence would have fertility effects. In the response filed by the Appellants on July 14, 2004, the Appellants provided further evidence which confirmed the 25520191.1

relationship between the claimed polynucleotide and fertility (See 1.132 declaration filed July 21, 2004 by Martin M. Matzuk and the publication Wu et al., Nature Genetics 33:187-191, 2003, a copy is submitted in Appendix B). In the publication, Wu et al provides evidence that if the claimed sequence or SEQ.ID.NO. 1 is absent in mice, the mice are infertile. Appellants assert that they have provided documentary evidence, which the Examiner appears to have overlooked. For example, in the Wu et al publication it clearly establishes that Zar1 homozygous knockout mice ( $Zar1^{-/-}$ ) are infertile, and Zar 1 and SEQ ID NO. 1 are the same polynucleotide, thus the present invention has utility, in that it has a “real world” use or application in the world of fertility. Thus, the present invention is reasonably correlated to a “specific biological activity,” which is fertility, and therefore satisfies requirements for utility under MPEP 2107.02. The statements of the specification which indicate that SEQ. ID. NO. 1 relates to fertility in conjunction with the additional evidence of the Wu et al publication that confirms that the absence of SEQ. ID. NO. 1 results in infertile mice, Appellants assert that a utility has been established that would enable one ordinarily skilled in the art to understand why the Appellants believe the claimed invention is useful.

In view of the above, Appellants assert that the Examiner has not established a proper 101 rejection because he has not met all the burdens, more specifically, the Examiner has not provided any evidence as required by MPEP under section 2107.02:

“A rejection based on lack of utility should not be maintained if an asserted utility for the claimed invention would be considered specific, substantial, and credible by a person of ordinary skill in the art in view of all evidence of record. Office personnel are reminded that they must treat as true a statement of fact made by an applicant in relation to an asserted utility, unless countervailing evidence can be provided that shows that one of ordinary skill in the art would have a legitimate basis to doubt the credibility of such a statement. Similarly, Office personnel must accept an opinion from a qualified expert that is based upon relevant facts whose accuracy is not being questioned; it is improper to disregard the opinion solely because of a disagreement over the significance or meaning of the facts offered.”

In view of the above statements, Appellants assert that the specification does disclose how to use the polynucleotide, SEQ. ID. NO. 1 and thus, sets forth a specific and substantial utility and/or a well-established utility.

**Claims 2, 3, 5-10 and 58-61 are separately patentable**

Claims 2, 3, 5-10 and 58-67 are rejected under 35 U.S.C. §101 as lacking a specific utility. Appellants respectfully disagree, as addressed above, and further notes that groups of the claims are separately patentable. The claims do not stand or fall together but are grouped as being separately patentable.

In particular, Appellant considers separate patentability for the grouping of the claims as follows: claims 2, 3 and 59; claims 5-7; and claims 8-10. All of the noted groups are separately patentable from each of the other groups because each grouping of claims concerns a different scope of the invention from the other groups, and the rejection of whether or not Appellant has provided a specific utility is directly related to their scope. Appellant reiterates that each group of the claims has an asserted utility.

**1. Claims 2 and 59 stand rejected**

Thus, the Examiner has not met the burden to establish a *prima facie* case of lack of utility. The Examiner has not provided documentary evidence as to why one of skill in the art would not understand the asserted utility of SEQ ID NO. 1 and polynucleotide (claim 2) that are fully complementary to SEQ ID NO. 1 (claim 59). Therefore, the rejection of these claims must be reversed.

**2. Claims 5-7 stand rejected**

Claim 5 recites an expression vector including the polynucleotide sequence of 2. Claim 6 recites that the expression vector is a plasmid and claim 7 recites that the expression vector is a viral vector. In the event that claim 2 falls, claims 5-7 are separately patentable because these vectors containing the polynucleotides can be used as contraceptives and/or to enhance fertility.

**3. Claims 8-10 stand rejected**

Claim 8 recites host cell contain the vector of claim 5. Claim 9 recites that the host cell is a prokaryotic cell and claim 10 recites that the host cell is an eukaryotic cell. In the event that claim 2 and/or claim 5 falls, claims 8-10 are separately patentable because the

recombinant proteins produce using the host cells can be used to produce antibodies that can be used as contraceptives.

**4. Claims 58 and 60 stand rejected**

Without agreeing with the substance of the rejection, Appellants have canceled claims 58 and 60 in the Amendment filed concurrently with this Brief.

**E. Issue Under 35 U.S.C. § 112, first paragraph.**

Claims 2, 3, 5-10 and 58-61 were rejected under 35 U.S.C. § 112, second paragraph, since the claimed invention lacks a specific or well established utility. Appellants traverse this rejection.

Appellants assert that the claimed invention has an asserted utility as discussed above under section D, issues under 35 U.S.C. § 101 of this Appeal Brief. Thus, in view of the above comments, Appellants request that the rejection be withdrawn in conjunction with the utility rejection.

**F. Issue Under 35 U.S.C. § 112, second paragraph.**

Claims 58-61 were rejected under 35 U.S.C. § 112, second paragraph. Appellants traverse this rejection.

Without agreeing with the substance of the rejection, Appellants have canceled claims 58, 60 and 61, and claim 59 was amended to correct the dependency in the Amendment filed concurrently with this Brief. In view of this Amendment, this rejection is now moot and Appellants request that the rejection be withdrawn.

**VIII. CLAIMS**

A copy of the claims, as amended, involved in the present appeal is attached hereto as Appendix A. As indicated above, the claims in Appendix A do include the amendments filed by Applicant on December 20, 2004, as well as the cancellation of claims 58, 60 and 61.

**IX. EVIDENCE**

Evidence pursuant to § 1.132 that was filed on July 21, 2004 and a copy of the publication Wu et al., Nature Genetics 33:187-191, 2003 are included as Appendix B.

**X. CONCLUSION**

Appellants have provided arguments that overcome the pending rejections. Appellants respectfully submit that the Action's conclusions that the claims should be rejected are unwarranted. It is therefore requested that the Board overturn the rejection of the Action. Since there are no outstanding prior art rejections, Appellants respectfully request that the Board recommend that this application proceed to allowance.

Please date stamp and return the enclosed postcard to evidence receipt of this document.

No related proceedings are referenced in II. above, or copies of decisions in related proceedings are not provided, hence no Appendix is included.

Dated: June 14, 2005

Respectfully submitted,



By   
Melissa W. Acosta  
Registration No.: 45,872  
FULBRIGHT & JAWORSKI L.L.P.  
Fulbright Tower  
1301 McKinney, Suite 5100  
Houston, Texas 77010-3095  
(713) 651-5151  
(713) 651-5246 (Fax)  
Agent for Applicant

**APPENDIX A**

**Claims Involved in the Appeal of Application Serial No. 09/830,810**

1. Canceled
2. (Previously presented) An isolated polynucleotide having the polynucleotide sequence set forth in SEQ ID NO: 1.
3. (Original) The polynucleotide of claim 2, wherein the polynucleotide is isolated from a mammalian cell.
4. Canceled
5. (Original) An expression vector including the polynucleotide of claim 2.
6. (Original) The vector of claim 5, wherein the vector is a plasmid.
7. (Original) The vector of claim 5, wherein the vector is a viral vector.
8. (Original) A host cell containing the vector of claim 5.
9. (Original) The host cell of claim 8, wherein the cell is prokaryotic.
10. (Original) The host cell of claim 8, wherein the cell is eukaryotic.

**Claims 11-57 (Canceled)**

58. Canceled
59. (Currently amended) An isolated polynucleotide that is fully complementary to the polynucleotide sequences of claim 2-~~or~~58.
60. Canceled
61. Canceled

**APPENDIX B**



Docket No.: HO-P01925US1  
(PATENT)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of:  
Martin M. Matzuk et al.

Application No.: 09/830,810

Art Unit: 1653

Filed: October 28, 1999

Examiner: Desai, Anand U.

For: **OVARY-SPECIFIC GENES AND PROTEINS**

**AMENDMENT**

MS AF  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

**INTRODUCTORY COMMENTS**

In response to the Office Action dated October 18, 2004, please amend the above-identified U.S. patent application as follows:

**Amendments to the Claims** are reflected in the listing of claims which begins on page 2 of this paper.

**Remarks/Arguments** begin on page 3 of this paper.

**AMENDMENTS TO THE CLAIMS**

1. Canceled
2. (Previously presented) An isolated polynucleotide having the polynucleotide sequence set forth in SEQ ID NO: 1.
3. (Original) The polynucleotide of claim 2, wherein the polynucleotide is isolated from a mammalian cell.
4. Canceled
5. (Original) An expression vector including the polynucleotide of claim 2.
6. (Original) The vector of claim 5, wherein the vector is a plasmid.
7. (Original) The vector of claim 5, wherein the vector is a viral vector.
8. (Original) A host cell containing the vector of claim 5.
9. (Original) The host cell of claim 8, wherein the cell is prokaryotic.
10. (Original) The host cell of claim 8, wherein the cell is eukaryotic.

Claims 11-57 (Canceled)

58. Canceled
59. (Currently amended) An isolated polynucleotide that is fully complementary to the polynucleotide sequences of claim 2-~~or~~ 58.
60. Canceled
61. Canceled

**REMARKS**

In response to the Final Office Action dated October 18, 2004 and the Advisory Action dated January 6, 2005, Applicants filed a Notice of Appeal which was received by the Patent Office on January 14, 2005. Applicants are contemporaneously filing their Appeal Brief, along with a Request for Extension of Time until June 14, 2005. A copy of this Amendment is being provided as an exhibit to that Appeal Brief.

Applicant believes no fee is due with this response. However, if a fee is due, please charge our Deposit Account No. 06-2375, under Order No. 10411469 from which the undersigned is authorized to draw.

Dated: June 14, 2005

Respectfully submitted,

By   
Melissa W. Acosta  
Registration No.: 45,872

FULBRIGHT & JAWORSKI L.L.P.  
1301 McKinney, Suite 5100  
Houston, Texas 77010-3095  
(713) 651-5407  
(713) 651-5246 (Fax)



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:  
Martin M. Matzuk et al.

Application No.: 09/830,810

Art Unit: 1653

Filed: October 28, 1999

Examiner: Desai, Anandu U

For: OVARY-SPECIFIC GENES AND PROTEINS

**1.132 DECLARATION OF DR. MARTIN M. MATZUK**

1. I, Martin M. Matzuk, do hereby declare and state the following:
2. I am a professor in the Department of Pathology at Baylor College of Medicine. I am skilled in the fields of fertility and embryonic development. (See attached Curriculum Vitae).
3. I am one of the inventors, and I have read the above-captioned patent application, as well as all Examiner's Actions and responses.
4. In the present application, myself and the Pei Wang isolated a polynucleotide sequence, SEQ.ID.NO.1. that was specifically and only expressed in the oocytes. This sequence is known as O1-180 and zygote arrest 1 (*Zar1*). Since the expression of this protein was similar to GDF-9, we assumed that it would have a similar function.
5. We performed several experiments to determine the function of *Zar1*. Such experiments included producing transgenic mice lacking *Zar1* or knockout mice (*Zar1*<sup>-/-</sup>). The *Zar1*<sup>-/-</sup> females were infertile compare to *Zar1*<sup>+/+</sup> and *Zar1*<sup>+/+</sup> females. (See page 188, second column of Wu et al., Nature Genetics 33:187-191, 2003).
6. I assert that the asserted utility in the patent application is a credible utility based upon our recent evidence as indicated in Wu et al., Nature Genetics 33:187-191, 2003.


7. I hereby declare that all statements made herein on my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under Title 18 § 1001 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

7-19-04

Date

Martin M. Matzuk

Martin M. Matzuk, M.D., Ph.D.



## CURRICULUM VITAE

**NAME:**

**ADDRESS:**

Martin Matthew Matzuk, M.D., Ph.D.  
Department of Pathology  
One Baylor Plaza  
Houston, TX 77030

**TELEPHONE:**

(713) 798-6451

**FAX:**

(713) 798-5833

**E-MAIL:**

mmatzuk@bcm.tmc.edu

**DATE OF BIRTH:**

January 30, 1960

**PLACE OF BIRTH:**

New Brunswick, New Jersey

### EDUCATION:

University of Chicago, B.A. with Honors, 1982 (Biology)

Washington University, M.D., Ph.D., 1989

Thesis: Structure-function studies of the glycoprotein hormones using mutagenesis,  
chimeric genes, and gene-transfer  
(Advisor, Dr. Irving Boime; Department of Pharmacology)

### PROFESSIONAL EXPERIENCE:

Undergraduate Research Assistant, University of Chicago, Dept. of Biochemistry  
(Advisor, Dr. Nicholas R. Cozzarelli), 1980-1982

Staff Research Associate, University of California, Berkeley, Dept. of Molecular Biology  
(Advisor, Dr. Nicholas R. Cozzarelli), 1982-1983

Teaching Assistant, Washington University School of Medicine,  
Pharmacology, 1985-1986

Clinical Pathology Resident, Dept. of Pathology and Laboratory Medicine,  
Hospital of the University of Pennsylvania, 1990-1991

Pathology Resident and Postdoctoral Fellow, Dept. of Path. and Molecular Genetics,  
Baylor College of Medicine, 1991-1993

Clinical Instructor, Dept. of Pathology, Baylor College of Medicine, 1992-1993

Director of Clin. Chem. and Diagnostic Immunol., Ben Taub Gen. Hosp., 1993-present

Assistant Professor, Departments of Pathology, Molecular and Human Genetics,  
and Molecular and Cellular Biology, Baylor College of Medicine, 1993-1995

Associate Professor, Departments of Pathology, Molecular and Human Genetics,  
and Molecular and Cellular Biology, Baylor College of Medicine, 1995-1998

Professor, Departments of Pathology, Molecular and Human Genetics,  
and Molecular and Cellular Biology, Baylor College of Medicine, 1998-present

Stuart A. Wallace Chair in Pathology,  
Baylor College of Medicine, 1999-present

**HONORS:**

Edmondson Research Fellowship, University of Chicago, 1981  
Medical Scientist Training Program, Washington University, 1983-1989  
Spencer T. and Ann W. Olin Fellowship, Washington University, 1989  
The Dr. Philip Needleman Prize For Excellence in Pharmacology Research;  
Washington University, 1990  
Resident Award at the 5th Annual Scientific Symposium of Alumni and  
Friends, Baylor College of Medicine, 1992  
John R. Rainey, MD, Resident Award at the 72nd Annual Meeting of the  
Texas Society of Pathologists, 1993  
Experimental Pathologist-in-Training Award, American Society for Investigative  
Pathology, 1993  
The Michael E. DeBakey, M.D., Excellence in Research Award,  
Baylor College of Medicine, 1995  
The Richard E. Weitzman Memorial Award, The Endocrine Society, 1996  
Inaugural Ernst Knobil Lecture, University of Pittsburgh, 1998  
The Bruce Stewart Memorial Lecture, American Society for  
Reproductive Medicine, 1998  
The HypoCCS Award, Eli Lilly, 1999  
O'Neal/Spjut Award, Baylor College of Medicine, 2001  
NIH MERIT Award, RO1HD33438, May 1, 2001  
Pfizer Outstanding Investigator Award, American Society for Investigative  
Pathology, 2002  
The Society for the Study of Reproduction Research Award, 2002

**TEACHING AND ADMINISTRATIVE RESPONSIBILITIES:**

Co-director, Medical Scientist Training Program, 1995-present  
Member, Medical Scientist Training Program Operating Committee, 1993-present  
Faculty Member, Developmental Biology Program, 1994-present  
Member, Animal Research Committee, 1994-present  
Instructor, Mammalian Molecular Genetics, 1993-1996  
Instructor, Developmental Biology I, 1994-1996  
Instructor, Reproductive Biology, 1997-present  
Laboratory Instructor, Medical School Pathology, 1994-1995  
Instructor, Pathology Resident Didactic Lecture Series, 1998-present  
Advisor, Graduate and Medical Students (Nine), 1994-present  
Member, Graduate Student Thesis Committees (Thirty-six), 1993-present  
Member of the Medical Staff, Ben Taub General Hospital, 1993-present  
Member of the Medical Staff, The Methodist Hospital, 1994-present  
Member, BaylorMedCare, 1997-1999  
Member, Faculty Search Committee, Molecular and Cellular Biology, 1995-1996  
Member, Faculty Search Committee, Molecular & Human Genetics, 1996-1997  
Member, Faculty Search Committee, Pathology, 1996-1997, 1997-1998  
Member, Intradepartmental Appointments and Promotions Committee, 1999-present  
Member, Standing Examination Committee, Molecular and Cellular Biology, 2000-  
present  
Member, Standing Examination Committee, Molecular and Human Genetics, 2002-present

**EXTERNAL THESIS ADVISORY COMMITTEES:**

“Thesis defense opponent”  
Dr. Kirsi Kanaanen  
Student of Dr. Ilpo Huhtaniemi  
Turku University, Finland, 1996

“Thesis examiner”  
Dr. Shyr-Yeu Lin  
Student of Dr. David DeKretser  
Monash University, Australia, 2003

**AD HOC REVIEWER:**

**Funding Agencies:**

NIH, National Institute of Child Health and Human Development  
NIH, National Cancer Institute  
The Lalor Foundation  
March of Dimes  
Marsden Fund, The Royal Society of New Zealand  
Michigan Diabetes Research and Training Center, Pilot/Feasibility Grants  
Michael Smith Foundation for Health Research  
MINERVA Cooperative Germany/Israel Research Grants  
National Health and Medical Research Council, Australia  
National Science Foundation  
The New Zealand Neurological Foundation  
North Carolina Biotechnology Center  
Research Grants Council of Hong Kong  
United States Department of Defense  
United States Department of Agriculture  
The Wellcome Trust

**AD HOC REVIEWER:**

Martin M. Matzuk, M.D., Ph.D. - Page 4

**Journals:**

*American Journal of Pathology*  
*Archives of Medical Research*  
*Biochimica et Biophysica Acta*  
*Biotechniques*  
*Biology of Reproduction*  
*Cell*  
*Cytokine*  
*Development*  
*Developmental Biology*  
*Developmental Dynamics*  
*The EMBO Journal*  
*Endocrine*  
*Endocrine Reviews*  
*Endocrinology*  
*European Journal of Endocrinology*  
*Gene*  
*Genes and Development*  
*Genome Research*  
*Genomics*  
*Human Reproduction*  
*Human Reproduction Update*  
*Journal of Andrology*  
*Journal of Cell Science*  
*Journal of Clinical Endocrinology and Metabolism*  
*Journal of Clinical Investigation*  
*Journal of Endocrinology*  
*Journal of Hepatology*  
*Mammalian Genome*  
*Mechanisms of Development*  
*Molecular and Cellular Biology*  
*Molecular and Cellular Endocrinology*  
*Molecular Endocrinology*  
*Molecular Human Reproduction*  
*Molecular Reproduction and Development*  
*Nature*  
*Nature Genetics*  
*Nature Medicine*  
*Nature Neuroscience*  
*Nature Reviews Molecular Cell Biology*  
*New England Journal of Medicine*  
*Oncogene*  
*Proceedings of the National Academy of Sciences*  
*Proceedings of the Society for Experimental Biology and Medicine*  
*Reproduction*  
*Science*  
*Trends in Endocrinology and Metabolism*  
*Trends in Genetics*

**INVITED LECTURES:**

UCLA Symposia on Molecular and Cellular Biology, Molecular Biology of Intracellular Protein Sorting and Organelle Assembly, Workshop, Taos, New Mexico, January 30-February 5, 1987

Gordon Research Conference, Reproductive Tract Biology, Plymouth, New Hampshire, July 6-10, 1992

European Science Foundation Scientific Program on Developmental Biology, Workshop on the Transforming Growth Factor  $\beta$  Family, Leuven, Belgium, November 19-21, 1992

Fifteenth Annual Workshop on Cell and Molecular Techniques, "Techniques in Cellular Signaling and Hormone Action", Houston, Texas, February 28-March 4, 1993

Southeast Regional Developmental Biology Conference, Athens, Georgia, May 14-16, 1993

Seventy-Fifth Meeting of the Endocrine Society, Plenary Session, "Gene Deletions and Endocrine Diseases", Las Vegas, Nevada, June 9-12, 1993

Eighth European Workshop on Molecular and Cellular Endocrinology of the Testis, De Panne, Belgium, March 27-31, 1994

Fifth International Workshop on Multiple Endocrine Neoplasia, Stockholm, Sweden, June 29-July 2, 1994

Serono Symposia, Tenth Ovarian Workshop: Frontiers in Ovarian Research, Ann Arbor, Michigan, July 21-23, 1994

International Workshop on Adrenal Glands, Vascular System, and Hypertension, Hong Kong, April 20-22, 1995

Third Conference of the International Union of Biochemistry and Molecular Biology, Singapore, April 23-27, 1995

24th Annual Reproductive Science Centers Director's Meeting, "Reproductive Developmental Biology", sponsored by the Reproductive Sciences Branch of the Center for Population Research, NICHD, San Francisco, July 14-15, 1995

Recent Progress in Hormone Research, 51st Conference, Stevenson, Washington, July 29-August 3, 1995

Serono Symposia, Life Cycle of the Ovarian Follicle, Fort Lauderdale, Florida, November 2-5, 1995

**INVITED LECTURES (cont):**

Keystone Symposia on Molecular & Cellular Biology,  
"Molecular and Developmental Biology of the Extracellular Matrix",  
Keystone Colorado, January 5-11, 1996

Triangle Consortium for Reproductive Biology, "The Development of the  
Reproductive Systems", Keynote Address,  
Chapel Hill, North Carolina, January 20, 1996

The American Association for the Advancement of Science  
Annual Meeting and Science Innovation Exposition,  
Baltimore, Maryland, February 8-13, 1996

The 25th Anniversary of the National Institutes of Child Health  
and Human Development Centers' Program,  
NICHD Molecular Endocrinology Workshop,  
Houston, Texas, May 21, 1996

Gordon Research Conference, Reproductive Tract Biology,  
Plymouth, New Hampshire, July 7-12, 1996

29<sup>th</sup> Annual Meeting of the Society for the Study of Reproduction,  
London, Ontario, July 27-30, 1996

Reproductive Endocrine Symposium, "Ovarian Messengers",  
University of Louisville, Louisville, Kentucky, September 27, 1996

3rd International Symposium on Biomedical Diagnostic and Prognostic Indicators,  
International Society for Preventative Oncology,  
Nice, France, October 26-28, 1996

Ares-Serono International Symposium on "Inhibin, Activin, and Follistatin...  
Recent Advances and Future Views",  
Tokushima, Japan, Nov. 9-10, 1996

HHMI-Sponsored Workshop on "Germ line Development"  
Chevy Chase, Maryland, December 1-4, 1996

American Society of Andrology, Annual Meeting,  
Baltimore, Maryland, February 23-25, 1997

"Hormones and Men's Health", Monash Medical Center and Prince Henry's Institute,  
Keynote Speaker, Melbourne, Australia, March 19-21, 1997

Ovarian Cancer Biology Workshop, National Cancer Institute,  
Bethesda, Maryland, April 6-8, 1997

VIth International Congress of Andrology,  
Salzburg, Austria, May 25-29, 1997

**INVITED LECTURES (cont):**

Seventy-Ninth Meeting of the Endocrine Society, Plenary Session,  
"Genetic Determination of Gonadal Development",  
Minneapolis, Minnesota, June 11-14, 1997

Bohan Visiting Scientist Lecture,  
University of Kansas Medical Center  
Kansas City, Kansas, July 14-15, 1997

American Urological Association Summer Research Conference,  
"Cell Biology of the Testis: Cell-Cell Interactions",  
Houston, Texas, August 8-10, 1997

Comitato Promotore Telethon,  
Telethon Comatti La Distrofia Muscolare E LE Altre Malattie Genetiche,  
Bologna, Italy, November 16-18, 1997

"Defining Cytokine Biology through Knockout and Transgenic Mouse Models",  
The National Cancer Institute,  
December 11, 1997

Society for Gynecological Investigation, Annual Meeting Course,  
"How to find a gene and beyond...",  
Atlanta, Georgia, March 11-14, 1998

"Reproduction in the 21st Century", International Symposium  
Sponsored by the Universidad de la Salle,  
Bogota, Columbia, March 13, 1998

Sixth Congress of the International Society of Gynecological Endocrinology,  
Plenary Session, "Molecular Biology in Gynecological Endocrinology",  
Crans-Montana, Switzerland, March 18-22, 1998

"First International Conference on the Genetic Origins of Premature Ovarian Failure",  
Sponsored by the Section on Women's Health,  
Developmental Endocrinology Branch,  
National Institute of Child Health and Human Development,  
Washington, D.C., April 2-4, 1998

Genetics Institute Discovery Research Retreat, "Signal Transduction",  
Ogunquit, Maine, May 20-22, 1998

"Frontiers in Reproduction: Molecular and Cellular Concepts and Applications",  
Woods Hole, Massachusetts, June 24-27, 1998

5th International Pituitary Congress,  
Naples, Florida, June 28-30, 1998

#### INVITED LECTURES (cont):

Society for the Study of Fertility, Annual Meeting,

Plenary Session, "Gonadal Development and Function"  
Glasgow, Scotland, July 6-8, 1998

XIIth Ovarian Workshop, Plenary Session,  
"Follicular Development and Oocyte Maturation"  
Houston, Texas, August 5-7, 1998

31<sup>st</sup> Annual Meeting of the Society for the Study of Reproduction,  
Techniques Workshop,  
"Gene Knockouts: Practical Considerations and Expectations",  
College Station, Texas, August 8, 1998

"The Biology of Menopause",  
Sponsored by the National Institute on Aging and Serono,  
Newport Beach, California, September 10-13, 1998

Inaugural Ernst Nobile Lecture, The University of Pittsburgh,  
Center for Research in Reproductive Physiology,  
Pittsburgh, Pennsylvania, September 16-17, 1998

37th Annual Meeting of the European Society for Paediatric Endocrinology,  
Plenary Lecture, Florence, Italy, September 24-27, 1998

Cold Spring Harbor Meeting, Germline Development,  
Cold Spring Harbor, New York, October 1-3, 1998

16th World Congress on Fertility and Sterility and American Society for Reproductive  
Medicine, 54th Annual Meeting, "Bruce Stewart Memorial Lecture",  
San Francisco, California, October 4-8, 1998

4th International Dahlem Symposium, "Cellular Signal Recognition and Transduction",  
Freie Universität Berlin, Berlin, Germany, October 8-10, 1998

Annual Meeting of the American Society for Gravitational and Space Biology,  
Plenary Lecture, Houston, Texas, October 28-31, 1998

Workshop on the Regulation of Reproductive Function,  
Annual Meeting of the Israel Fertility Association,  
Jerusalem, Israel, April 12-14, 1999

The Third Annual HypoCCS Symposium, "Regulation of Pituitary Hormone Secretion"  
Venice, Italy, April 15-17, 1999

1999 North American Inhibin and Activin Congress,  
Chicago, Illinois, May 21-23, 1999

**INVITED LECTURES (cont):**

International Workshop on Early Folliculogenesis and Oocyte Formation, Development and Arrest: Basic and Clinical Aspects, Ares-Serono Foundation, London, England, June 10-11, 1999

32<sup>nd</sup> Annual Meeting of the Society for the Study of Reproduction, Pullman, Washington, July 31-August 3, 1999

Genetic Regulation of Gametogenesis and Development, The Royal Society of Edinburgh, Edinburgh, Scotland, September 23-24, 1999

"Reproductive Sciences 2000: Technology in the Service of Biology", The Annual Meeting of the Society of Gynecologic Investigation, Salt Lake City, Utah, February 23-26, 2000

"The Ovary: from Organogenesis to Function to Failure"  
Sponsored by the Section on Women's Health  
Developmental Endocrinology Branch  
National Institute of Child Health and Human Development,  
Washington, D.C., March 30-31, 2000

"Molecular Laboratory Research Course for Clinical Endocrinologists", The University of Hong Kong  
Hong Kong, May 18-20, 2000

"Molecular Medicine for the Practicing Clinician", Centre of Endocrinology and Diabetes  
Hong Kong, May 21, 2000

"Embryogenesis Begins During Oogenesis. Follicle Development and Oocyte Fate", Bologna, Italy, May 26-27, 2000

Frontiers in Reproduction Symposium, Oocytes and Human Reproduction,  
"Egg Futures: 2000 and Beyond"  
Boston, Massachusetts, June 15-17, 2000

Eighty-Second Meeting of the Endocrine Society, Plenary Session,  
"Regulation of Inhibin/Activin Action in Reproduction",  
Toronto, Canada, June 21-24, 2000

Gordon Research Conference, Gametogenesis and Embryogenesis,  
New London, Connecticut, July 2-6, 2000

Ares-Serono Foundation Workshop, "Molecular Genetics of Human Reproduction"  
Heronissos Beach, Crete, September 15-17, 2000

Round Table Conference, "Alternative Approaches to IVF", Sponsored by N.V. Organon,  
Lisbon, Portugal, September 22-23, 2000

**INVITED LECTURES (cont):**

“Inhibins, Activins, and Follistatin”, Ares-Serono Symposia,  
Melbourne, Australia, October 26-28, 2000

11th Congress of the International Society for Endocrinology,  
Sydney, Australia, October 29-November 3, 2000

“Montreal Research Day”,  
Sponsored by the University of Montreal and McGill University,  
Montreal, Canada, January 17, 2001

European Society of Human Reproduction and Embryology  
“Mammalian oogenesis and folliculogenesis: in vivo and in vitro approaches”,  
Lisbon, Portugal, April 6-7, 2001

XIIth International Workshop on the Development and Function of  
the Reproductive Organs, Ares-Sorono Foundation,  
Jerusalem, Israel, April 30-May 3, 2001

“First Annual Advances in Contraceptive Help”,  
Sponsored by Wyeth Ayerst Pharmaceuticals  
Charleston, South Carolina, May 20-22, 2001

17th Annual Meeting of the European Society of Human Reproduction and Embryology,  
Lausanne, Switzerland, July 1-4, 2001

FASEB Conference, “The TGF- $\beta$  superfamily: signaling and development”,  
Tucson, Arizona, July 7-12, 2001

7<sup>th</sup> Annual Mouse Developmental Genetics Course,  
Albert Einstein College of Medicine  
Bronx, NY, August 26 – September 1, 2001

Symposium for the Inauguration of The Weitzmann Women’s Health Research Center,  
“Fertility and Gender-Specific Cancer”,  
Rehovot, Israel, November 11, 2001

Ernst Schering Research Foundation Workshop  
“The Future of the Oocyte: Basic and Clinical Aspects”  
Berlin, Germany, January 30 - February 1, 2002

21st Joint Meeting of the British Endocrine Societies,  
Harrogate, United Kingdom, April 8-11, 2002

Colloque 2002 de la Société Française de Génétique,  
“Reproduction et lignée germinale: génétique et pathologies, éthique”  
Pasteur Institute, Paris, France, April 10-11, 2002

**INVITED LECTURES (cont):**

Experimental Biology 2002,  
"Translating the genome",  
American Society for Investigative Pathology  
New Orleans, Louisiana, April 20-24, 2002

Texas Forum of Female Reproduction,  
Keynote Speaker,  
Houston, Texas, May 2-3, 2002

CEJKOVICE 2002, "From Oocyte to Embryonic Stem Cell:  
A Lesson from Pluripotency",  
Southern Moravia, Czech Republic, June 6 - 9, 2002

Gordon Research Conference, Gametogenesis and Embryogenesis,  
New London, Connecticut, June 30-July 4, 2002

35th Annual Meeting of the Society for the Study of Reproduction,  
Baltimore, Maryland, July 28-31, 2002

5<sup>th</sup> Copenhagen Workshop on Carcinoma *in situ* and Cancer of the Testis,  
Copenhagen, Denmark, August 29-31, 2002

TuBS Symposium on Genetic Engineering of Mice for Biology and Disease Models  
Mauno Koivisto Center, BioCity  
Turku, Finland, November 28-29, 2002

Testis Workshop, "Functional Genomics of Male Reproduction"  
Phoenix, Arizona, March 26-29, 2003

Inaugural speaker, "Billie A. Field Memorial Lectureship",  
College of Veterinary Medicine,  
University of Illinois at Urbana – Champaign  
Urbana, Illinois, April 22, 2003

The Twenty-Second Annual University of Kentucky Symposium in  
Reproductive Sciences, "Functional Genomics and Mammalian Reproduction"  
Lexington, Kentucky, May 16-17, 2003

International Conference on the Female Reproductive Tract,  
Monastery of Seeon, Germany, May 30-June 2, 2003

Ares-Serono Workshop on Human Implantation, "Genomics/Proteomics of the ovary",  
Madrid, Spain, June 28, 2003

"State of the A.R.T." meeting titled "Communication between oocyte and ovary",  
Madrid, Spain, June 28-29, 2003

**INVITED LECTURES (cont):**

International Ares-Serono Workshop on "Inhibins, Activins, and Follistatins"  
Siena, Italy, July 3-4, 2003

FASEB Conference, "TGF- $\beta$  Superfamily: Signaling and Development",  
Tucson, Arizona, July 12-17, 2003

Eppigenetic contribution to our understanding of the oocyte,  
The Jackson Laboratory  
Bar Harbor, Maine, August 2-3, 2003

59<sup>th</sup> Annual Meeting of the American Society for Reproductive Medicine,  
"Reproductive Medicine and ART: Basic Science and Future Promise"  
San Antonio, Texas, October 11-15, 2003

Cytokine-regulated gene expression at the crossroads of innate immunity,  
inflammation and fertility  
New York University School of Medicine  
New York City, October 17-18, 2003

Annual meeting, Taiwanese Society for Reproductive Medicine  
Taipei, Taiwan, December 20-21, 2003

Reproductive Medicine Conference "Updates in Infertility Treatment"  
Marco Island, Florida, January 22-24, 2004

Annual Meeting of the "Hinterzartener Kreis fuer Krebsforschung/Cancer Research"  
"Growth factors, Repair and Cancer"  
Cadenabbia, Italy, April 22-25, 2004

Gordon Research Conference, Gametogenesis and Embryogenesis,  
New London, Connecticut, June 6-11, 2004

XIII International Workshop on the Development and Function of the  
Reproductive Organs  
Copenhagen, Denmark, June 12-16, 2004

37th Annual Meeting of the Society for the Study of Reproduction,  
Minisymposium on "Oocyte-somatic cell interactions in folliculogenesis",  
Vancouver, British Columbia, August 1-4, 2004

Third International Symposium "Assisted Conception and Reproductive Biology:  
Two Perspectives, One Vision"  
Sponsored by Technobios Procreazione  
"Maternal effect genes during preimplantation development",  
Bologna, Italy, November 18-20, 2004

**GRANTS AWARDED (\* = Current Support):**

National Institutes of Health, National Institute of Child Health and Human Development; K11HD00960;  
"Developmental and Functional Roles of Activin and Inhibin";  
August 1, 1991-July 31, 1996. I declined years 4-5.

National Institutes of Health, National Institute of Child Health and Human Development; NRSA F32HD07539;  
"Developmental and Functional Roles of Activin and Inhibin";  
Awarded May 1991; I declined.

The Lalor Foundation; "Developmental and Functional Roles of Activin and Inhibin in Mammalian Reproduction";  
June 1, 1991-May 31, 1992; Renewal June 1, 1992-May 31, 1993

\*National Institutes of Health, National Institute of Child Health and Human Development; R01HD32067;  
"Functional Analysis of Activins During Development";  
August 1, 1994-July 31, 1997; Renewal December 1, 1998 – May 31, 2004;  
Renewal June 1, 2004-March 31, 2009

\*National Institutes of Health, National Cancer Institute; R01CA60651;  
"Mouse Models to Study Gonadal Tumor Development";  
August 1, 1993-May 31, 1997; Renewal June 1, 1997 - March 31, 2001;  
Renewal April 1, 2001 – March 31, 2006

\*National Institutes of Health, National Institute of Child Health and Human Development; R37 HD33438;  
"Analysis of Reproductive Function Using Transgenic Mice";  
May 1, 1996-April 30, 2001; Renewal May 1, 2001 – April 30, 2006

\*National Institutes of Health, National Institute of Child Health and Human Development; U54 HD07495 (PI, Dr. Bert O'Malley);  
"Center for Reproductive Biology Research Grant";  
April 1, 1996-March 31, 1998; Renewal April 1, 1998 - March 31, 2004;  
Renewal April 1, 2004 – March 31, 2009 (years 32-36)

Genetics Institute, Cambridge Massachusetts; "Functional Analysis of Transforming Growth Factor  $\beta$  Superfamily Members - I";  
October 1, 1996-March 31, 1999; Renewal July 1, 1999 – June 30, 2000

Metamorphix, Baltimore, Maryland; "Functional Analysis of Transforming Growth Factor  $\beta$  Superfamily Members - II";  
October 1, 1996-September 30, 1997;  
Renewal February 1, 1998 - January 31, 1999

National Institutes of Health, National Institute of Child Health and Human Development; RO3 HD37231;  
"Identification and Analysis of Novel Ovarian Genes";  
December 15, 1998 - November 30, 2000

**GRANTS AWARDED, continued:**

\*Wyeth-Ayerst, Women's Health Research Institute;  
"Analysis of Putative Female Infertility-Associated Genes";  
April 1, 1999 – March 31, 2003; Renewal April 1, 2003 – March 31, 2004

Moran Foundation, Lia Lechago Fund for Cardiovascular Research  
July 1, 1999 – June 30, 2000

\*National Institutes of Health, National Institute of Child Health and Human Development; R01 HD42500;  
"Regulation of Key Processes in Oocyte Biology"  
April 1, 2003 – March 31, 2008

**ADVISORY/EDITORIAL BOARDS, CHAIR, AND CONSULTANT ACTIVITIES:**

Children's Nutrition Research Center Advisory Board, Baylor College of Medicine,  
Houston, Texas, 1997-present

Research Consultant, Genetics Institute, Cambridge, Massachusetts, 1996-2000

Advisory Committee, The Oregon Regional Primate Research Center,  
The Oregon Health Sciences University, Portland, Oregon, 1998-present

Research Consultant, Wyeth-Ayerst Research, 1999-present

Advisory Committee, Career Awards in the Biomedical Sciences,  
Burroughs Wellcome Fund, 1999-present

Editorial Board, Journal of Endocrinology, 2001-present

Editorial Board, Molecular Endocrinology, 2001-present

Committee on New Frontiers in Contraceptive Research,  
Institute of Medicine/National Academy of Sciences,  
Board on Health Science Policy, 2003-2004

Co-Chair, Advisory Committee, Career Awards in the Biomedical Sciences,  
Burroughs Wellcome Fund, 2004-2006

Co-Chair, 3<sup>rd</sup> Advances in Contraceptive Health Conference,  
Sponsored by Wyeth Research, Tucson, AZ  
February 22-24, 2004

**ELECTED SOCIETIES:**

Sigma Xi, 1982  
The Endocrine Society, 1991-present  
American Society for Investigative Pathology, 1993-present  
Society for the Study of Reproduction, 1999-present

**PATENTS:**

Boime, I. and Matzuk, M.M. "Modified Forms of Reproductive Hormones"; U.S. Patent and Trademark Office; Patent Number 5,177,193; Issued January 5, 1993.

Boime, I. and Matzuk, M.M. "DNA encoding reproductive hormones and expression using a minigene"; U.S. Patent and Trademark Office; Patent Number 5,405,945; Issued April 11, 1995.

Boime, I., Matzuk, M.M., and Keene, J.L. "Follicle stimulating hormone-glycosylation analogs", U.S. Patent and Trademark Office, Patent Number 6,306,654; Issued October 23, 2001

Wakil, S., Matzuk, M.M., and Abu-Elheiga, L. "ACC2-knockout mice and uses thereof", U.S. Patent and Trademark Office; Patent Number 6,548,738; Issued April 15, 2003

Matzuk, M.M., Elvin, J.A., and Wang, P. "Assay for growth differentiation factor 9", U.S. Patent and Trademark Office, Patent Number 6,680,174; Issued January 20, 2004

Wakil, S.J., Matzuk, M.M., and Abu-Elheiga, L. "Acetyl-coenzyme a carboxylase 2 as a target in the regulation of fat burning, fat accumulation, energy homeostasis, and insulin action", U.S. Patent and Trademark Office; Patent Number 6,734,337; Issued May 11, 2004

**PUBLICATIONS:**

1. Dean, F., Krasnow, M.A., Otter, R., **Matzuk, M.M.**, Spengler, S.J., and Cozzarelli, N.R. *Escherichia coli* type-1 topoisomerases: identification, mechanism, and role in recombination. *Cold Spring Harbor Symposia on Quantitative Biology*, Vol. 47, 769-777 (1983).
2. Krasnow, M.A., **Matzuk, M.M.**, Dungan, J.M., Benjamin, H.W., and Cozzarelli, N.R. Site-specific recombination by Tn3 resolvase: models for pairing of recombination sites. In *Mechanisms of DNA Replication and Recombination*, (N.R. Cozzarelli, ed.), pp. 637-659, A.R. Liss, New York (1983).
3. Benjamin, H.W., **Matzuk, M.M.**, Krasnow, M.A., and Cozzarelli, N.R. Recombination site selection by Tn3 resolvase: topological tests of a tracking mechanism. *Cell* 40, 147-158 (1985).
4. **Matzuk, M.M.** and Saper, C.B. Preservation of hypothalamic dopaminergic neurons in Parkinson's disease. *Ann. Neurol.* 18, 552-555 (1985).
5. Corless, C.L., **Matzuk, M.M.**, Ramabhadran, T.V., Krichevsky, A., and Boime, I. Gonadotropin beta subunits determine the rate of assembly and the oligosaccharide processing of hormone dimer in transfected cells. *J. Cell Biol.* 104, 1173-1181 (1987).
6. **Matzuk, M.M.**, Krieger, M., Corless, C.L., and Boime, I. Effects of preventing O-linked glycosylation on the secretion of human chorionic gonadotropin in Chinese hamster ovary cells. *Proc. Natl. Acad. Sci. USA* 84, 6354-6358 (1987).
7. **Matzuk, M.M.**, Kornmeier, C.M., Whifield, G.K., Kourides, I.A., and Boime, I. The glycoprotein  $\alpha$  subunit is critical for secretion and stability of the thyrotropin  $\beta$  subunit. *Molec. Endocrinol.* 2, 95-100 (1988).
8. **Matzuk, M.M.** and Boime, I. The role of the asparagine-linked oligosaccharides of the  $\alpha$  subunit in the secretion and assembly of human chorionic gonadotropin. *J. Cell Biol.* 106, 1049-1059 (1988).
9. Campbell, R.K., **Matzuk, M.M.**, Canfield, R.E., Boime, I., and Moyle, W.E. Use of monoclonal antibodies and mutagenesis to study the structure of human chorionic gonadotropin. In *Placental Protein Hormones* (M. Mochizuki and R. Hussa, eds.), pp. 123-132, Elsevier Science Publishers B.V., Amsterdam (1988).
10. **Matzuk, M.M.** and Boime, I. Site-specific mutagenesis defines the intracellular role of the asparagine-linked oligosaccharides of chorionic gonadotropin  $\beta$  subunit. *J. Biol. Chem.* 263, 17106-17111 (1988).
11. **Matzuk, M.M.**, Keene, J.L., and Boime, I. Site specificity of the chorionic gonadotropin N-linked oligosaccharides in signal transduction. *J. Biol. Chem.* 264, 2409-2414 (1989).
12. Keene, J.L., **Matzuk, M.M.**, Otani, T., Fauser, B.C.J.M., Galway, A.W., Hsueh, A.J.W., and Boime, I. Expression of biologically active human follitropin in Chinese hamster ovary cells. *J. Biol. Chem.* 264, 4769-4775 (1989).
13. **Matzuk, M.M.** and Boime, I. Mutagenesis and gene transfer define site-specific roles of the gonadotropin oligosaccharides. *Biol. Reprod.* 40, 48-53 (1989).

14. Bielinska, M., **Matzuk, M.M.**, and Boime, I. Site-specific processing of the N-linked oligosaccharides of the human chorionic gonadotropin  $\alpha$  subunit. *J. Biol. Chem.* 264, 17113-117118 (1989).
15. **Matzuk, M.M.**, Spangler, M.M., Camel, M., Saganuma, N., and Boime, I. Mutagenesis and chimeric genes define determinants in the  $\beta$  subunits of human chorionic gonadotropin and lutropin for secretion and assembly. *J. Cell Biol.* 109, 1429-1438 (1989).
16. Saganuma, N., **Matzuk, M.M.**, and Boime, I. Effects of disulfide bond interruption on the assembly and secretion of human chorionic gonadotropin  $\beta$  subunit. *J. Biol. Chem.* 264, 19302-19307 (1989).
17. Keene, J.L., **Matzuk, M.M.**, and Boime, I. Expression of recombinant human choriogonadotropin in Chinese hamster ovary glycosylation mutants. *Molec. Endocrinol.* 3, 2011-2017 (1989).
18. **Matzuk, M.M.**, Hsueh, A.J.W., LaPolt, P., Tsafiriri, A., Keene, J.L., and Boime, I. The biological role of the carboxyl-terminal extension of human chorionic gonadotropin  $\beta$  subunit. *Endocrinol.* 126, 376-383 (1990).
19. Moyle, W.R., **Matzuk, M.M.**, Campbell, R.K., Coglianii, E., Dean-Emig, D.M., Krichevsky, A., Barnett, R.W., and Boime, I. Localization of residues which confer antibody binding specificity using human chorionic gonadotropin/luteinizing hormone  $\beta$  subunit chimeras and mutants. *J. Biol. Chem.* 265, 8511-8518 (1990).
20. Campbell, R.K., **Matzuk, M.M.**, Dean-Emig, D.M., Coglianii, E., Myers-Shamy, R.V., Krichevsky, A., Boime, I., Barnett, R., and Moyle, W.R. Use of  $\beta$ -subunit chimeras to study the structures of glycoprotein hormones and to develop a model of the  $\beta$ -subunit. In *Glycoprotein Hormones: Structure, Synthesis, and Biological Function* (W.W. Chin and I. Boime, eds.), pp. 37-43, Serono Symposia, USA, Norwell, MA (1990).
21. **Matzuk, M.M.**, Bielinska, M., and Boime, I. Mutagenesis and gene transfer define the subunit-specific role of the gonadotropin asparagine-linked oligosaccharides. In *Glycoprotein Hormones: Structure, Synthesis, and Biological Function* (W.W. Chin and I. Boime, eds.), pp. 111-121, Serono Symposia, USA, Norwell, MA (1990).
22. **Matzuk, M.M.**, Shlomchik, M., and Shaw, L.M. Making digoxin therapeutic drug monitoring more effective. *Therapeutic Drug Monitoring* 13, 215-219 (1991).
23. **Matzuk, M.M.** and Bradley, A. Cloning of the human activin receptor cDNA reveals high evolutionary conservation. *Biochimica et Biophysica Acta* 1130, 105-108 (1992).
24. **Matzuk, M.M.** and Bradley, A. Structure of the mouse activin receptor type II gene. *Biochem. Biophys. Rsch. Commun.* 185, 404-413 (1992).

25. **Matzuk, M.M.**, Finegold, M.J., Su, J.-G.J., Hsueh, A.J.W., and Bradley, A.  $\alpha$ -Inhibin is a tumour suppressor gene with gonadal specificity in mice. *Nature* 360, 313-319 (1992).
26. **Matzuk, M.M.** and Bradley, A. Identification and analysis of tumour suppressor genes using transgenic mouse models. *Seminars in Cancer Biology* 5, 37-45 (1994).
27. Trudeau, V.L., **Matzuk, M.M.**, Hache, R.J.G., and Renaud, L.P. Overexpression of activin- $\beta$ A subunit mRNA is associated with decreased activin type II receptor mRNA levels in the testes of  $\alpha$ -inhibin-deficient mice. *Biochem. Biophys. Rsch. Commun.* 203, 105-112 (1994).
28. Keene, J.L., Nishimori, K., Galway, A.B., **Matzuk, M.M.**, Hsueh, A.J.W., and Boime, I. Recombinant deglycosylated human FSH is an antagonist of human FSH action in cultured rat granulosa cells. *Endocrinology Journal* 2, 175-180 (1994).
29. Incerti, B., Dong, J., Borsani, G., and **Matzuk, M.M.** Structure of the mouse growth/differentiation factor 9 gene. *Biochimica et Biophysica Acta* 1222, 125-128 (1994).
30. Shikone, T., **Matzuk, M.M.**, Perlas, E., Finegold, M.J., Vale, W., Bradley, A., and Hsueh, A.J.W. Characterization of gonadal tumor cell lines from inhibin- $\alpha$  deficient mice: the role of activin as an autocrine growth factor. *Molecular Endocrinology* 8, 983-995 (1994).
31. Vassalli, A., **Matzuk, M.M.**, Gardner, H.A.R., Lee, K.-F., and Jaenisch, R. Activin/inhibin  $\beta$ B subunit gene disruption leads to defects in eyelid development and female reproduction. *Genes and Development* 8, 414-427 (1994).
32. **Matzuk, M.M.** Transgenic animals and the study of gonadal function. In *Molecular and Cellular Endocrinology of the Testis* (G. Verhoeven and U.-F. Habenicht, eds.), pp. 251-271, Springer-Verlag, Berlin (1994).
33. **Matzuk, M.M.**, Finegold, M.J., Mather, J.P., Krummen, L., Lu, H., and Bradley, A. Development of cancer cachexia-like syndrome and adrenal tumors in inhibin-deficient mice. *Proc. Natl. Acad. Sci. USA* 91, 8817-8821 (1994).
34. **Matzuk, M.M.** Gene deletion models to understand cytokine function. In *Human Cytokines: Their Role in Disease and Therapy* (B.B. Aggarwal and R.K. Puri, eds.), pp. 651-662, Blackwell Scientific Publications, Inc., Cambridge, MA. (1995).
35. Kumar, T.R., Donehower, L.A., Bradley, A., and **Matzuk, M.M.** Transgenic mouse models for tumour suppressor genes. *J. Internal Medicine* 238, 233-238 (1995).
36. **Matzuk, M.M.** Functional analysis of mammalian members of the transforming growth factor  $\beta$  superfamily. *Trends in Endocrinology and Metabolism* 6, 120-127 (1995).
37. **Matzuk, M.M.**, Kumar, T. R., Vassalli, A., Bickenbach, J.R., Roop, D.R., Jaenisch, R., and Bradley, A. Functional analysis of activins in mammalian development. *Nature* 374, 354-356 (1995).
38. **Matzuk, M.M.**, Kumar, T. R., and Bradley, A. Different phenotypes for mice deficient in either activins or activin receptor type II. *Nature* 374, 356-360 (1995).

39. Matzuk, M.M., Lu, H., Vogel, H., Sellheyer, K., Roop, D.R., and Bradley, A. Multiple defects and perinatal death in mice deficient in follistatin. Nature 374, 360-363 (1995).
40. Feng, W., Matzuk, M.M., Mountjoy, K., Bedows, E., Rudden, R.W., and Boime, I. The asparagine-linked oligosaccharides of the human chorionic gonadotropin  $\beta$  subunit facilitate correct disulfide bond pairing. J. Biol. Chem. 270, 11851-11859 (1995).
41. Matzuk, M.M., Finegold, M.J., Mishina, Y., Bradley, A., and Behringer, R. R. Synergistic effects of inhibins and Mullerian inhibiting substance on testicular tumorigenesis. Molecular Endocrinology 9, 1337-1345 (1995).
42. Kumar, T.R., Kelly, M., Mortrud, M., Low, M.J., and Matzuk, M.M. Cloning of the mouse  $\beta$  gonadotropin subunit genes, I. Structure of the follicle-stimulating hormone  $\beta$ -subunit-encoding gene. GENE 166, 333-334 (1995).
43. Kumar, T.R. and Matzuk, M.M. Cloning of the mouse gonadotropin  $\beta$  subunit genes, II. Structure of the luteinizing hormone  $\beta$ -subunit-encoding gene. GENE 166, 335-336 (1995).
44. Matzuk, M.M., Kumar, T.R., Shou, W., Coerver, K.A., Lau, A., Behringer, R.R., and Finegold, M.J. Transgenic models to study the roles of inhibins and activins in reproduction, oncogenesis, and development. Recent Progress in Hormone Research 51, 123-157 (1996).
45. Coerver, K.A., Woodruff, T.K., Finegold, M.J., Mather, J.P., Bradley, A., and Matzuk, M.M. Activin signaling through activin receptor type II causes the cachexia-like symptoms in inhibin-deficient mice. Molecular Endocrinology 10, 534-543 (1996).
46. Lau, A., Nishimori, K., and Matzuk, M.M. Structure of the mouse activin  $\beta$ C gene. Biochimica et Biophysica Acta 1307, 145-148 (1996).
47. Nishimori, K. and Matzuk, M.M. Transgenic mice in the analysis of reproductive development and function. Reviews of Reproduction 1, 203-212 (1996).
48. Lieberman, M.W., Wiseman, A.L., Shi, Z-Z., Carter, B.Z., Barrios, R., Ou, C-N., Chevez-Barrios, P., Wang, Y., Habib, G.M., Goodman, J.C., Huang, S.L., Lebovitz, R.M., and Matzuk, M.M. Growth retardation and cysteine deficiency in  $\gamma$ -glutamyl transpeptidase-deficient mice. Proc. Natl. Acad. Sci. USA 93, 7923-7926 (1996).
49. Kumar, T.R., Wang, Y., and Matzuk, M.M. Gonadotropins are essential modifier factors for gonadal tumor development in inhibin-deficient mice. Endocrinology 137, 4210-4216 (1996).
50. Lebovitz, R.M., Zhang, H., Vogel, H., Cartwright, Jr., J., Dionne, L., Lu, N., Huang, S., and Matzuk, M.M. Neurodegeneration, myocardial injury, and perinatal death in mitochondrial superoxide dismutase-deficient mice. Proc. Natl. Acad. Sci. USA 93, 9782-9787 (1996).
51. Roberts, V.S., Bentley, C.A., Guo, Q., Matzuk, M.M., and Woodruff, T.K. Tissue-specific binding of radiolabeled activin-A by activin receptors and follistatin in postimplantation rat and mouse embryos. Endocrinology 137, 4201-4209 (1996).

52. Nishimori, K., Young, L.J., Guo, Q., Wang, Z., Insel, T.R., and **Matzuk, M.M.** Oxytocin is required for nursing but is not essential for parturition or reproductive behavior. Proc. Natl. Acad. Sci. USA 21, 11699-11704 (1996).
53. Mishina, Y., Rey, R., Finegold, M.J., **Matzuk, M.M.**, Josso, N., Cate, R.L., and Behringer, R.R. Genetic analysis of the Müllerian-inhibiting substance signal transduction pathway in mammalian sexual differentiation. Genes and Development 10, 2577-2587 (1996).
54. Dong, J., Albertini, D.F., Nishimori, K., Kumar, T.R., Lu, N., and **Matzuk, M.M.** Growth differentiation factor-9 is required during early ovarian folliculogenesis. Nature 383, 531-535 (1996).
55. Nilsson, C., Pettersson, K., Millar, R.P., Coerver, K.A., **Matzuk, M.M.**, and Huhtaniemi, I.T. Worldwide frequency of a common genetic variant of luteinizing hormone: an international collaborative research. Fertility and Sterility 67, 998-1004 (1997).
56. Kumar, T.R., Wang, Y., Lu, N., and **Matzuk, M.M.** Follicle stimulating hormone is required for ovarian follicle maturation but not male fertility. Nature Genetics 15, 201-204 (1997).
57. Shou, W., Guo, Q., Dong, J., and **Matzuk, M.M.** Transgenic Models for Studying Adrenal, Ovarian, and Testicular Cancer. In Adrenal Gland, Vascular System, and Hypertension (G.P. Vinson and D.C. Anderson, eds.), Journal of Endocrinology Ltd., Bristol, England, pp. 281-292 (1997).
58. Young, L.J., Winslow, J.T., Wang, Z., Gingrich, B., Guo, Q., **Matzuk, M.M.**, and Insel, T.R. Gene targeting approaches to neuroendocrinology: oxytocin, maternal behavior and affiliation. Hormones and Behavior 31, 221-231 (1997).
59. Lau, A.L., Shou, W., Guo, Q., and **Matzuk, M.M.** Transgenic approaches to study the functions of the transforming growth factor  $\beta$  superfamily members. In Inhibin, Activin, and Follistatin (T. Aono, H. Sugino, and W.W. Vale, eds.), Springer, New York, pp. 220-243 (1997).
60. Shou, W.S., Woodruff, T.K. and **Matzuk, M.M.** Role of androgens in testicular tumor development in inhibin-deficient mice. Endocrinology 138, 5000-5005 (1997).
61. Ben-Arie, N., Bellen, H.J., McCall, A.E., Gordadze, P.R., Armstrong, D.L., Guo, Q., **Matzuk, M.M.**, and Zoghbi, H.Y. Math1 is essential for genesis of cerebellar granule neurons. Nature 390, 169-172 (1997).
62. Zhou, J., Kumar, T.R., **Matzuk, M.M.**, and Bondy, C. Insulin-like growth factor I regulates gonadotropin responsiveness in the murine ovary. Molecular Endocrinology 11, 1924-1933 (1997).
63. Guo, Q., Kumar, T.R., Woodruff, T.K., Hadsell, L., DeMayo, F., and **Matzuk, M.M.** Overexpression of mouse follistatin causes reproductive defects in transgenic mice. Molecular Endocrinology 12, 96-106 (1998).
64. Li, Q., Karam, S.M., Coerver, K.A., **Matzuk, M.M.**, and Gordon, J.I. Stimulation of activin receptor II signaling pathways inhibits differentiation of multiple gastric epithelial cell lineages. Molecular Endocrinology 12, 181-192 (1998).

65. Palapattu, G.S., Bao, S., Kumar, T.R., and **Matzuk, M.M.** Transgenic mouse models for tumor suppressor genes. Cancer Detection and Prevention 22, 75-86 (1998).
66. Kumar, T.R. and **Matzuk, M.M.** Transgenic mice as models of disease. In Textbook of Molecular Medicine (J.L. Jameson, ed.), pp. 97-110, Humana Press, Totowa, New Jersey (1998).
67. Draper, L.B., **Matzuk, M.M.**, Roberts, V.J., Cox, E., Weiss, J., Mather, J.P. and Woodruff, T.K. Identification of an inhibin receptor in gonadal tumors from inhibin  $\alpha$ -subunit knockout mice. J. Biol. Chem 273, 398-403 (1998).
68. Shou, W., Aghdasi, B., Armstrong, D.L., Guo, Q., Bao, S., Charng, M-J., Mathews, L.S., Schneider, M.D., Hamilton, S.L., and **Matzuk, M.M.** Cardiac defects and altered ryanodine receptor function in mice lacking FKBP12. Nature 391, 489-492 (1998).
69. Habib, G.M., Shi, Z.-Z., Cuevas, A., Guo, Q., **Matzuk, M.M.**, and Lieberman, M.W. Leukotriene D<sub>4</sub> and cystinyl-bis-glycine metabolism in membrane-bound-dipeptidase deficient mice. Proc. Natl. Acad. Sci. USA 95, 4859-4863 (1998).
70. Ferguson, C.A., Tucker, A.S., Christensen, L., Lau, A.L., **Matzuk, M.M.**, and Sharpe, P.T. Activin is an essential early mesenchymal signal in tooth development that is required for patterning of the murine dentition. Genes and Development 12, 2636-2649 (1998).
71. Matilla, A., Roberson, E.D., Banfi, S., Morales, J., Armstrong, D.L., Burright, E.N., Orr, H.T., Sweatt, J.D., Zoghbi, H.Y. and **Matzuk, M.M.** Mice lacking ataxin-1 display learning deficits and decreased hippocampal paired-pulse facilitation. Journal of Neuroscience 18, 5508-5516 (1998).
72. Kumar, T.R., Low, M.J. and **Matzuk, M.M.** Genetic rescue of follicle stimulating hormone  $\beta$ -deficient mice. Endocrinology 139, 3289-3295 (1998).
73. Jhaveri, S., Erzurumlu, R.S., Chiaia, N., Kumar, T.R., and **Matzuk, M.M.** Defective whisker follicles and altered brainstem patterns in activin and follistatin knockout mice. Molecular and Cellular Neuroscience 12, 206-219 (1998).
74. Bassing, C.H., Shou, W., Muir, S., Heitman, J., **Matzuk, M.M.**, and Wang, X.-F. FKBP12 is not required for the modulation of transforming growth factor beta receptor I signaling activity in embryonic fibroblasts and thymocytes. Cell Growth and Differentiation 9, 223-228 (1998).
75. Elvin, J.A. and **Matzuk, M.M.** Mouse models of ovarian failure. Reviews of Reproduction (1998) 3, 183-195.
76. **Matzuk, M.M.**, Dionne, L., Guo, Q., Kumar, T.R., and Lebovitz, R.M. Ovarian function in superoxide dismutase 1 and 2 knockout mice. Endocrinology 139, 4008-4011 (1998).
77. Dube, J.L., Wang, P., Elvin, J., Lyons, K.M., Celeste, A.J., and **Matzuk, M.M.** The bone morphogenetic protein 15 gene is X-linked and expressed in oocytes. Molecular Endocrinology 12, 1809-1817 (1998).

78. Carabatsos, M.J., Elvin, J., **Matzuk, M.M.**, and Albertini, D.F. Characterization of oocyte and follicle development in growth differentiation factor-9 deficient mice. Developmental Biology 204, 373-384 (1998).
79. **Matzuk, M.M.** Transgenic models in the study of reproduction. In Fertility and Reproductive Medicine (R.D. Kempers, J. Cohen, A.F. Haney, and J.B. Younger, ed.), pp. 17-25, Elsevier Science B.V. (1998).
80. Winslow, J.T., Young, L.J., Hearn, E., Gingrich, B., Wang, Z., Guo, Q., **Matzuk, M.M.**, and Insel, T.R. Phenotypic expression of an oxytocin peptide null mutation in mice. Advances in Experimental Medicine and Biology 449, 241-243 (1998).
81. Liu, D., **Matzuk, M.M.**, Sung, W.K., Guo, Q., Wang, P., and Wolgemuth, D.J. Cyclin A1 is specifically required for meiosis in the male. Nature Genetics 20, 377-388 (1998).
82. Chang, H., Huylebroeck, D., Verschueren, K., Guo, Q., **Matzuk, M.M.**, and Zwijsen, A. Smad5 knockout mice die at mid-gestation due to multiple embryonic and extraembryonic defects. Development 126, 1631-1642 (1999).
83. **Matzuk, M.M.** and Kumar, T.R. Mouse models to study pituitary hormone gene expression and function. In Regulation of Pituitary Hormone Secretion, (ed. P. Beck-Peccoz), Bioscientifica Ltd., Bristol, U.K., pp. 197-215 (1999).
84. Elvin, J.A., Yan, C., Wang, P., Nishimori, K., and **Matzuk, M.M.** Molecular characterization of the follicle defects in the growth differentiation factor-9-deficient ovary. Molecular Endocrinology, 13, 1018-1034 (1999).
85. Elvin, J.A., Clark, A.T., Wang, P., Wolfman, N.M. and **Matzuk, M.M.** Paracrine actions of growth differentiation factor-9 in the mammalian ovary. Molecular Endocrinology, 13, 1035-1048 (1999).
86. Kumar, T.R., Palapattu, G., Wang, P., Woodruff, T.K., Boime, I., Byrne, M.C., and **Matzuk, M.M.** Transgenic models to study gonadotropin function: the role of FSH in gonadal growth and tumorigenesis. Molecular Endocrinology 13, 851-865 (1999).
87. Gold, B.G., Densmore, V., Shou, W., **Matzuk, M.M.**, and Gordon, H.S. Immunophilin FK506-binding protein 52 (not FK506-binding protein 12) mediates the neurotrophic action of FK506. The Journal of Pharmacology and Experimental Therapeutics 289, 1202-1210 (1999).
88. Lau, A., and **Matzuk, M.M.** Transgenic models in the study of reproduction. Gravitational and Space Biology Bulletin, 12, 75-82 (1999).
89. Elvin, J.A. and **Matzuk, M.M.** Transgenic models to study reproduction, oncogenesis, and development. In Biology of Menopause (ed. F.L. Bellino), Springer-Verlag, New York, pp. 225-237 (2000).
90. Elvin, J.A., Yan, C., and **Matzuk, M.M.** Oocyte-expressed TGF- $\beta$  superfamily members in female fertility. Molecular and Cellular Endocrinology 159, 1-5 (2000).

91. Ben-Arie, N., Hassan B.A., Bermingham, N.A., Malicki, D.M., Armstrong, D., **Matzuk, M.M.**, Bellen, H.J., and Zoghbi, H.Y. Functional conservation of atonal and Math1 in the CNS and PNS. Development 127, 1039-1048 (2000).
92. Kumar, T.R. and **Matzuk, M.M.** Gene Knockout Models to Study the Hypothalamus-Pituitary-Gonadal Axis. In Gene Engineering and Molecular Models in Endocrinology (M.A. Shupnik, ed.), The Humana Press, Inc., Totowa, NJ, pp. 167-216 (2000).
93. Chang, H., Zwijnen, A., Vogel, H., Huylebroeck, D., and **Matzuk, M.M.** Smad5 is essential for left-right asymmetry in mice. Developmental Biology, 219, 71-78 (2000).
94. Davis, A.A., **Matzuk, M.M.**, and Reh, T.A. Activin A promotes progenitor differentiation into photoreceptors in rodent retina. Molecular and Cellular Neuroscience, 15, 11-21(2000).
95. Winslow, J.T., Hearn, E.F., Ferguson, J., Young, L.J., **Matzuk, M.M.**, and Insel, T.R. Infant vocalization, adult aggression and fear behavior of an oxytocin null mutant mouse. Hormones and Behavior 37, 145-155 (2000).
96. **Matzuk, M.M.** Revelations of ovarian follicle biology from gene knockout mice. Molecular and Cellular Endocrinology 163, 61-66 (2000).
97. Lin, X., Wei, G., Shi, Z., Dryer, L., Esko, J.D., Wells, D.E., and **Matzuk, M.M.** Disruption of gastrulation and heparin sulfate biosynthesis in EXT1-deficient mice. Developmental Biology, 15, 299-311 (2000).
98. Brown, C.W., Houston-Hawkins, D.E., Woodruff, T.K., and **Matzuk, M.M.** Insertion of *Inhbb* into the *Inhba* locus rescues the *Inhba*-null phenotype and reveals new activin functions. Nature Genetics 25, 453-457 (2000).
99. Ferguson, J.N., Young, L.J., Hearn, E.F., **Matzuk, M.M.**, Insel, T.R., and Winslow, J.T. Social amnesia in mice lacking the oxytocin gene. Nature Genetics 25, 284-288 (2000).
100. Kirkpatrick, L.L., **Matzuk, M.M.**, Dodds, D.C., and Perin, M.S. Biochemical Interactions of the Neuronal Pentraxins: Neuronal Pentraxin (NP) Binds to Taipoxin and Taipoxin-associated calcium-binding protein 49 via NP1 and NP2. J. Biol. Chem. 275, 17786-17792 (2000).
101. Cipriano, S.C., Chen, L., Kumar, T.R., and **Matzuk, M.M.** Follistatin is a modulator of gonadal tumor progression and the activin-induced wasting syndrome in inhibin-deficient mice. Endocrinology 141, 2319-2327 (2000).
102. Lorenzetti, D., Watase, K., Xu, B., **Matzuk, M.M.**, and Zoghbi, H.Y. Repeat instability and motor incoordination in mice with a targeted expanded CAG repeat in the Scal1 locus. Hum. Mol. Genet. 9, 779-785 (2000).
103. Pierson, T.M., Wang, Y., DeMayo, F.J., **Matzuk, M.M.**, Tsai, S.Y., and O'Malley, B.W. Regulable expression of inhibin A in wild-type and inhibin  $\alpha$  null mice. Molecular Endocrinology, 14, 1075-1085 (2000).

104. Shi, Z.Z., Osei-Frimpong, J., Kala, G., Kala, S.V., Barrios, R.J., Habib, G.M., Lukin, D.J., Danney, C.M., **Matzuk, M.M.**, and Lieberman, M.W. Glutathione synthesis is essential for mouse development but not for cell growth in culture. Proc. Natl. Acad. Sci., USA 97, 5101-5106 (2000).
105. Lau, A.L., Kumar, T.R., Nishimori, K., Bonadio, J., and **Matzuk, M.M.** Activin  $\beta$ C and activin  $\beta$ E genes are not essential for mouse liver growth, differentiation, and regeneration. Molecular and Cellular Biology, 20, 6127-6137 (2000).
106. **Matzuk, M.M.** In search of binding-identification of inhibin receptors (Editorial) Endocrinology 141, 2281-2284 (2000).
107. Elvin, J.A., Yan, C., and **Matzuk, M.M.** Growth differentiation factor-9 stimulates progesterone synthesis in granulosa cells via a prostaglandin E2/EP2 receptor pathway. Proc. Natl. Acad. Sci., USA 97, 10288-10293 (2000).
108. Kumar, T.R., Wiseman, A.L., Kala, G., Kala, S.V., **Matzuk, M.M.** and Lieberman, M.W. Reproductive defects in  $\gamma$ -glutamyl transpeptidase-deficient mice. Endocrinology 141, 4270-4277 (2000).
109. Yan, C. and **Matzuk, M.M.** Transgenic models of ovarian failure. Journal of the Society for Gynecologic Investigation 8, 30-33 (2001).
110. Chang, H. and **Matzuk, M.M.** Smad5 is required for primordial germ cell development. Mechanisms of Development 104, 61-67 (2001).
111. Elvin, J.A. and **Matzuk, M.M.** Control of ovarian function. In: Contemporary Endocrinology: Transgenics in Endocrinology (**M.M. Matzuk**, C.W. Brown, T.R. Kumar, eds.) Humana Press, Totowa, NJ, pp. 61-89 (2001).
112. Contemporary Endocrinology: Transgenics in Endocrinology (**M.M. Matzuk**, C.W. Brown, T.R. Kumar, eds.) Humana Press, Totowa, NJ (2001).
113. Wreford, N.G., Kumar, T.R., **Matzuk, M.M.**, and de Kretser, D.M. Analysis of the testicular phenotype of the follicle stimulating hormone (FSH)  $\beta$  subunit knock-out and the activin type IIA receptor knock-out mice by stereological analysis. Endocrinology 142, 2916-2920 (2001).
114. Pierson, T.M. and **Matzuk, M.M.** Transgenic mouse models to study inhibin and activin. In: Inhibins, Activins, and Follistatin in Human Reproductive Physiology (eds. S. Muttukrishna and W. Ledger), Imperial College Press, London, pp. 279-327 (2001).
115. Abu-Elheiga, L., **Matzuk, M.M.**, Abo-Hashema, K.A.H., and Wakil, S.J. Continuous fatty acid oxidation and reduced fat storage in mice lacking acetyl-CoA carboxylase 2. Science 291, 2613-2616 (2001).
116. Chang, H., Lau, A.L., and **Matzuk, M.M.** Studying TGF- $\beta$  superfamily signaling by knockouts and knockins. Molecular and Cellular Endocrinology 180, 39-46 (2001).

117. Yan, C., Wang, P., DeMayo, J., DeMayo, F.J., Elvin, J.A., Carino, C., Prasad, S.V., Skinner, S.S., Dunbar, B.S., Dube, J.L., Celeste, A.J., and **Matzuk, M.M.** Synergistic roles of bone morphogenetic protein 15 and growth differentiation factor 9 in ovarian function. Molecular Endocrinology 15, 854-866 (2001).
118. Cipriano, S.C., Chen, L., Burns, K.H., Koff, A., and **Matzuk, M.M.** Inhibin and p27 interact to regulate gonadal tumorigenesis. Molecular Endocrinology 15, 985-996 (2001).
119. Burns, K.H., Yan, C., Kumar, T.R., and **Matzuk, M.M.** Analysis of ovarian gene expression in follicle stimulating hormone- $\beta$  knockout mice. Endocrinology 142, 2742-2751 (2001).
120. Kumar, T.R., Varani, S., Wreford, N.G., Telfer, N.M., de Kretser, D.M., and **Matzuk, M.M.** Male reproductive phenotypes in double mutant mice deficient in FSH $\beta$  and activin receptor IIA. Endocrinology 142, 3512-3518 (2001).
121. Rajkovic, A., Yan, C., Klysik, M., and **Matzuk, M.M.** Discovery of germ cell-specific transcripts by expressed sequence tag database analysis. Sterility and Fertility 76, 550-554 (2001).
122. Jeffs, B., Meeks, J.J., Ito, M., Martinson, F.A., **Matzuk, M.M.**, Jameson, J.L., and Russell, L.D. Blockage of the rete testis and efferent ductules by ectopic Sertoli and Leydig cells causes infertility in *Dax1* deficient male mice. Endocrinology 142, 4486-4495 (2001).
123. Shi, Z-Z., Han, B., Habib, G.M., **Matzuk, M.M.**, Lieberman, M.W. Disruption of  $\gamma$ -glutamyl leukotrienase results in disruption of leukotriene D<sub>4</sub> synthesis in vivo and attenuation of the acute inflammatory response. Molecular and Cellular Biology 21, 5389-5395 (2001).
124. **Matzuk, M.M.** Eggs in the balance. Nature Genetics 28, 300-301 (2001).
125. Durlinger, A.L., Gruijters, M.J., Kramer, P., Karels, B., Kumar, T.R., **Matzuk, M.M.**, Rose, U.M., de Jong, F.H., Uilenbroek, J.T., Grootegoed, J.A., and Themmen, A.P. Anti-Mullerian hormone attenuates the effects of FSH on follicle development in the mouse ovary. Endocrinology 142, 4891-4899 (2001).
126. Yan, C., Pendola, F.L., Jacob, R., Lau, A.L., Eppig, J.J., and **Matzuk, M.M.** *Oosp1* encodes a novel mouse oocyte-secreted protein. Genesis 31, 105-110 (2001).
127. Wu, X. and **Matzuk, M.M.** GDF-9 and BMP-15: Oocyte Organizers. Reviews in Endocrine & Metabolic Disorders 3, 27-32 (2002).
128. Suzumori, S., Yan, C., **Matzuk, M.M.**, and Rajkovic, A. *Nobox* is a homeobox-containing gene preferentially expressed in primordial and growing oocytes. Mechanisms of Development 111, 137-141 (2002).
129. Rajkovic, A. and **Matzuk, M.M.** Functional analysis of oocyte-expressed genes using transgenic models. Molecular and Cellular Endocrinology 112, 173-177 (2002).
130. Rajkovic, A., Yan, C., Yan, W., Klysik, M., and **Matzuk, M.M.** *Obox*, a family of homeobox genes preferentially expressed in germ cells. Genomics 79, 711-717 (2002).

131. Rajkovic, A., Lee, J.H., Yan, C., and **Matzuk, M.M.** The Ret Finger Protein-Like 4 gene, *Rfp14*, encodes a putative E3 ubiquitin-protein ligase expressed in adult germ cells. *Mechanisms of Development* 187, 5-9 (2002).
132. Varani, S. and **Matzuk, M.M.** Phenotypic effects of knockout of oocyte-specific genes. *Ernst Schering Research Foundation Workshop* 41, 63-79 (2002).
133. Burns, K.H., Owens, G., Fernandez, J.M., Nilson, J.H., and **Matzuk, M.M.** Characterization of integrin expression in the mouse ovary. *Biology of Reproduction* 67, 743-751 (2002).
134. Varani, S., Elvin, J.A., Yan, C., DeMayo, J., DeMayo, F.J., Horton, H.F., Byrne, M.C., and **Matzuk, M.M.** Knockout of pentraxin 3, a downstream target of growth differentiation factor-9, causes female subfertility. *Molecular Endocrinology* 16, 1154-1167 (2002).
135. Burns, K.H. and **Matzuk, M.M.** Genetic models for the study of gonadotropin actions. *Endocrinology* 143, 2823-2835 (2002).
136. Yan, W., Rajkovic, A., Viveiros, M.M., Burns, K.H., Eppig, J.J., and **Matzuk, M.M.** Identification of Gasz, an evolutionarily conserved gene expressed exclusively in germ cells and encoding a protein with four ankyrin repeats, a sterile-alpha motif, and a basic leucine zipper. *Molecular Endocrinology* 16, 1168-1184 (2002).
137. Harlow, C.R., Davidson, L., Burns, K.H., Yan, C., **Matzuk, M.M.**, and Hillier, S.G. FSH and TGF- $\beta$  superfamily members regulate granulosa cell connective tissue growth factor gene expression *in vitro* and *in vivo*. *Endocrinology* 143, 3316-3325 (2002).
138. **Matzuk, M.M.**, Burns, K.H., Viveiros, M.M., and Eppig, J.J. Intercellular communication in the mammalian ovary: oocytes carry the conversation. *Science* 296, 2178-2180 (2002).
139. Yan, W., Burns, K.H., Ma, L., and **Matzuk, M.M.** Identification of *Zfp393*, a germ cell-specific gene encoding a novel zinc finger protein. *Mechanisms of Development* 118, 233-239 (2002).
140. Burns, K.H. and **Matzuk, M.M.** Transgenic models for the study of human reproduction. In *Biotechnology of Human Reproduction* 2<sup>nd</sup> ed. (A. Revelli, I. Tur-Kaspa, J.G. Holte, and M. Massobrio, eds), pp. 413-435, The Parthenon Publishing Group, New York (2002).
141. Chang, H., Brown, C.W., and **Matzuk, M.M.** Genetic analysis of the mammalian TGF- $\beta$  superfamily. *Endocrine Reviews* 23, 787-823 (2002).
142. **Matzuk, M.M.** and Lamb, D.J. Genetic dissection of mammalian fertility pathways. *Nature Medicine* 8, S41-S49 (2002).
143. Burns, K.H., DeMayo, F.J., **Matzuk, MM.** Transgenic technology, cloning and germ cell transplantation. In *Molecular Biology in Reproductive Medicine: Molecular Cellular and Genetic Fundamentals*, second edition (B.C.J.M. Fauser, ed.), pp. 169-195, The Parthenon Publishing Group, New York (2003).
144. Nakamura, M., **Matzuk, M.M.**, Gerstmayer, B., Bosio, A., Lauster, R., Miyachi, Y., Werner, S., and Paus, R. Control of pelage hair follicle development and cycling by complex interactions between follistatin and activin. *FASEB Journal* 17, 497-499 (2003).

145. Wu, X., Viveiros, M., Eppig, J.J., Bai, Y., Fitzpatrick, S., and **Matzuk, M.M.** Zygote arrest 1 (*Zar1*) is a novel maternal effect gene critical for the oocyte-to-embryo transition. Nature Genetics 33, 187-191 (2003).
146. Burns, K.H. and **Matzuk, M.M.** Oocyte development and maturation. In: Encyclopedia of Hormones (Henry, H.L. and Norman, A.W., eds.), pp. 66-72, Academic Press, San Diego (2003).
147. Lukas-Croisier, C., Lasala, C., Nicaud, J., Bedecarras, P., Kumar, T.R., Dutertre, M., **Matzuk, M.M.**, Picard, J.Y., Josso, N., and Rey, R. Follicle-stimulating hormone increases testicular anti-Mullerian hormone (AMH) production through Sertoli cell proliferation and a nonclassical cyclic adenosine 5'-monophosphate-mediated activation of the AMH gene. Molecular Endocrinology 17, 550-561 (2003).
148. Suzumori, N., Burns, K.H., Yan, W., and **Matzuk, M.M.** RFPL4 interacts with oocyte proteins of the ubiquitin-proteasome degradation pathway. Proc. Natl. Acad. Sci., USA 100, 550-555 (2003).
149. Wu, M.H., Rajkovic, A., Burns, K.H., Yan, W., Lin, Y.N., and **Matzuk, M.M.** Sequence and expression of testis-expressed gene 14 (Tex14): a gene encoding a protein kinase preferentially expressed during spermatogenesis. Mechanisms of Development: Gene Expression Patterns 3, 231-236 (2003).
150. Yan, W., Burns, K.H., and **Matzuk, M.M.** Genetic engineering to study testicular tumorigenesis. Acta Pathologica Microbiologica et Immunologica Scandinavica 111, 174-183 (2003).
151. Burns, K.H., Viveiros, M.M., Ren, Y., Wang, P., DeMayo, F., Frail, D.E., Eppig, J.J., and **Matzuk, M.M.** Roles of NPM2 in chromatin and nucleolar organization in oocytes and embryos. Science 300, 633-636 (2003).
152. **Matzuk, M.M.**, Hadsell, L.A., De Mayo, F., and Kumar, T.R. Overexpression of human chorionic gonadotropin causes multiple reproductive defects in transgenic mice. Biology of Reproduction 69, 338-346 (2003).
153. Chirala, S.S., Chang, H., **Matzuk, M.M.**, Abu-Elheiga, L., Mao, J., Mahon, K., Finegold, M., and Wakil, S.J. De novo fatty acid synthesis is essential for embryonic development: fatty acid synthase null mutants and most of the heterozygotes die in utero. Proc. Natl. Acad. Sci., USA 100, 6358-6363 (2003).
154. Yan, W., Assadi, A.H., Wynshaw-Boris, A., Eichele, G., **Matzuk, M.M.**, and Clark, G.D. Previously uncharacterized roles of platelet-activating factor acetylhydrolase 1b complex in mouse spermatogenesis. Proc. Natl. Acad. Sci., USA 100, 7189-7194 (2003).
155. Wu, X., Wang, P., Brown, C.A., Zilinski, C.A., and **Matzuk, M.M.** Zygote arrest 1 (*Zar1*) is an evolutionarily conserved gene expressed in vertebrate ovaries. Biology of Reproduction 69, 861-867 (2003).
156. Brown, C.W., Li, L., Houston-Hawkins, D.E., and **Matzuk, M.M.** Activins are critical modulators of growth and survival. Molecular Endocrinology 17, 2404-2417 (2003).

157. Bernard D.J., Burns, K.H., Haupt, B., **Matzuk, M.M.**, and Woodruff, T.K. Normal reproductive function in InhBP/p120-deficient mice. Molecular and Cellular Biology 23, 4882-4891 (2003).
158. Burns, K.H., Agno, J.E., Chen, L., Haupt, B., Ogbonna, S., Korach, K.S., and **Matzuk, M.M.** Sexually dimorphic roles of steroid hormone receptor signaling in gonadal tumorigenesis. Molecular Endocrinology 17, 2039-2052 (2003).
159. Burns, K.H., Agno, J.E., Sicinski, P., and **Matzuk, M.M.** Cyclin D2 and p27 are tissue-specific regulators of tumorigenesis in inhibin  $\alpha$  knockout mice. Molecular Endocrinology 17, 2053-2069 (2003).
160. Yan, W., Ma, L., Burns, K.H., and **Matzuk, M.M.** HILS1 is a spermatid-specific linker histone H1-like protein implicated in chromatin remodeling during spermiogenesis. Proc. Natl. Acad. Sci., USA 100, 10546-10551 (2003).
161. Burns, K.H., Owens, G.E., Ogbonna, S., Nilson, J.H., **Matzuk, M.M.** Expression profiling analyses of gonadotropin responses and tumor development in the absence of inhibins. Endocrinology 144, 4492-4507 (2003).
162. Kumar, T.R., Agno, J., Janovic, J., Conn, P.M. and **Matzuk, M.M.** Regulation of FSH $\beta$  and GnRH receptor gene expression in activin receptor II knockout male mice. Molecular and Cellular Endocrinology 212, 19-27 (2003).
163. Burns, K.H. and **Matzuk, M.M.** The application of gene ablation and related technologies to the study of ovarian physiology. In: The Ovary (Leung, P.C.K. and Adashi, E.Y., eds.), pp. 411-432, Academic Press, San Diego (2004).
164. Roy, A., Yan, W., Burns, K.H., and **Matzuk, M.M.** *Tektin3* encodes an evolutionarily conserved putative testicular microtubule-related protein expressed preferentially in male germ cells. Molecular Reproduction and Development 67, 295-302 (2004).
165. Yan, W., Ma, L., **Matzuk, M.M.** Identification and characterization of Gasz orthologs in pufferfish, zebrafish, and frog. Biology of Reproduction 70, 1619-1625 (2004).
166. Yao, H.H.C., **Matzuk, M.M.**, Jorgez, C., Menke, D.B., Page, D.C., Swain, A., and Capel, B. Follistatin Operates Downstream of Wnt4 in Mammalian Ovary Organogenesis. Developmental Dynamics 230, 210-215 (2004).
167. Jorgez, C.J., Klysik, M., Jamin, S.P., Behringer, R.R., and **Matzuk, M.M.** Granulosa cell-specific inactivation of follistatin causes female fertility defects. Molecular Endocrinology 18, 953-967 (2004).
168. Pangas, S.A. and **Matzuk, M.M.** Genetic models for transforming growth factor  $\beta$  superfamily signaling in ovarian follicle development. Molecular and Cellular Endocrinology. In press (2004).
169. Tang, W., Ingalls, C.P., Durham, W.J., Snider, J., Reid, M.B., Wu, G., **Matzuk, M.M.** and Hamilton, S.L. Altered excitation-contraction coupling with skeletal muscle specific FKBP12 deficiency. FASEB Journal In press (2004).

170. De La Fuente, R., Viveiros, M.M., Burns, K.H., Adashi, E.Y., **Matzuk M.M.**, and Eppig, J.J. Global silencing of transcription in mammalian oocytes does not require major chromatin remodeling. Manuscript submitted.
171. Yan, W., Lang, M., Burns, K.H., and **Matzuk, M.M.** An oocyte-specific oligoadenylyate synthase-like protein, OAS1D, inhibits the interferon/oligoadenylyate synthetase/RNase L-mediated cell destruction pathway in mouse oocytes. Manuscript submitted.
172. Yan, W., Lang, M., Burns, K.H., and **Matzuk, M.M.** Haploinsufficiency of kelch-like 10 causes infertility in male mice. Proc. Natl. Acad. Sci., USA 101, 7793-7798 (2004).
173. Wu, X., Chen, L., Brown, C.A., Yan, C., and **Matzuk, M.M.** Interrelationship of Growth Differentiation Factor 9 and Inhibin in Early Folliculogenesis and Ovarian Tumorigenesis in Mice. Molecular Endocrinology 18, 1509-1519 (2004).
174. Yan, C., Elvin, J.A., Lin, Y-N., Hadsell, L.A., DeMayo, F.J., and **Matzuk, M.M.** Regulation of growth differentiation factor 9 expression in oocytes *in vivo*: A key role of the E-box. Manuscript submitted.
175. Wang, X., Jorgez, C.J., Suomalainen, M., **Matzuk, M.M.**, Werner, S., and Thesleff, I.. Modulation of TGF $\beta$  signaling by follistatin is required for the morphogenesis of mouse molar teeth. Manuscript submitted.
176. McKenzie, L.J., Jorgez, C.J., Cisneros, P., Buster, J.E., Amato, P., **Matzuk, M.M.**, and Carson, S.A. Follicular fluid prostanoid PGE2: a possible marker for embryo selection? Manuscript submitted.
177. Tominaga, K., Ikeno, Y., Ikeda, T., Hawks, C., **Matzuk, M.M.**, Pereira-Smith, O.M. MRG15 regulates embryonic development and proliferation. Manuscript submitted.
178. Tominaga, K., Magee, D.M., **Matzuk, M.M.**, and Pereira-Smith, O.M. PAM14, a novel MRG and Rb associated protein, is not required for development and T-cell function in mice. Molecular and Cellular Biology In press (2004).
179. Pangas, S.A., Jorgez, C.J., and **Matzuk, M.M.** Growth differentiation factor 9 regulates expression of the bone morphogenetic protein antagonist, gremlin. Journal of Biological Chemistry In press (2004).
180. Combelles, C.M.H., Carabatsos, M.J., Kumar, T.R., **Matzuk, M.M.**, and Albertini, D.F. Hormonal control of somatic cell oocyte interactions during ovarian follicle development. Molecular Reproduction and Development In press (2004).
181. Wang, X-P., Suomalainen, M., Jorgez, C.J., **Matzuk, M.M.**, Werner, S., and Thesles, I. Follistatin inhibits ameloblast differentiation by antagonizing BMP4 signaling and is responsible for the enamel-free area formation in mouse incisors. Manuscript submitted.
182. Su, Y-Q., Wu, X., O'Brien, M.J., Pendola, F.L., Denegre, J.N., **Matzuk, M.M.**, and Eppig, J.J. Synergistic roles of BMP15 and GDF9 in the development and function of the oocyte-cumulus cell complex in mice: genetic evidence for an oocyte-granulosa cell regulatory loop. Manuscript submitted.

183. Ware, S.M., Chen, C., Houston-Hawkins, D.E., Shen, M.M., **Matzuk, M.M.**, and Brown, C.W. Growth differentiation factor 3 regulates gastrulation and embryonic axis formation. Manuscript submitted.
184. Wang, Y., Cabello, O.A., Harrison, W., Largaespada, D.A., **Matzuk, M.M.**, and Overbeek, P.A. Rapid identification of transposition in mice using a coat color marker tagged on the Y chromosome. Manuscript submitted.
185. Rajkovic, A., Pangas, S.A., Ballow, D., Suzumori, N., and **Matzuk, M.M.** Nobox regulates oocyte-specific gene expression in early folliculogenesis. Manuscript submitted.
186. Ma, X., Dong, Y., **Matzuk, M.M.**, and Kumar, T.R. Targeted disruption of luteinizing hormone  $\beta$  subunit leads to hypogonadism, defects in gonadal steroidogenesis and infertility. Manuscript submitted.
187. McKenzie, L.J., Pangas, S.A., Carson, S.A., Kovanci, E., Cisneros, P., Buster, J.E., Amato, P., and **Matzuk, M.M.** Human granulosa cell gene expression: A predictor of fertilization and embryo selection in women undergoing *in vitro* fertilization. Manuscript submitted.
188. Pangas, S.A., Yan, W., **Matzuk, M.M.**, and Rajkovic, A. Restricted germ cell expression of a gene encoding a novel mammalian HORMA domain-containing protein. Manuscript submitted.
189. Burns, K.H. and **Matzuk, M.M.** Pre-implantation embryogenesis. In The Physiology of Reproduction, 3<sup>rd</sup> ed. (Neill, J., ed.), pp. \_\_\_\_-\_\_\_\_, Academic Press, San Diego (2004).

# Zygote arrest 1 (*Zar1*) is a novel maternal-effect gene critical for the oocyte-to-embryo transition

Xuemei Wu<sup>1</sup>, Maria M. Viveiros<sup>2,5</sup>, John J. Eppig<sup>2</sup>, Yuchen Bai<sup>3</sup>, Susan L. Fitzpatrick<sup>3</sup> & Martin M. Matzuk<sup>1,4</sup>

Published online 21 January 2003; doi:10.1038/ng1079

**The female gamete (the oocyte) serves the distinct purpose of transmitting the maternal genome and other maternal factors that are critical for post-ovulation events<sup>1–4</sup>. Through the identification and characterization of oocyte-specific factors, we are beginning to appreciate the diverse functions of oocytes in ovarian folliculogenesis, fertilization and embryogenesis<sup>5,6</sup>. To understand these processes further, we identified genes called zygote arrest 1 (*Zar1* and *ZAR1* in mouse and human, respectively) as novel oocyte-specific genes. These encode proteins of 361 amino acids and 424 amino acids, respectively, which share 59% amino-acid identity and an atypical plant homeo-domain (PHD) motif<sup>7</sup>. Although *Zar1*-null (*Zar1*<sup>−/−</sup>) mice are viable and grossly normal, *Zar1*<sup>−/−</sup> females are infertile. Ovarian development and oogenesis through the early stages of fertilization are evidently unimpaired, but most embryos from *Zar1*<sup>−/−</sup> females arrest at the one-cell stage. Distinct pronuclei form and DNA replication initiates, but the maternal and paternal genomes remain separate in arrested zygotes. Fewer than 20% of the embryos derived from *Zar1*<sup>−/−</sup> females progress to the two-cell stage and show marked reduction in the synthesis of the transcription-requiring complex<sup>8</sup>, and no embryos develop to the four-cell stage. Thus, *Zar1* is the first identified oocyte-specific maternal-effect gene that functions at the oocyte-to-embryo transition and, as such, offers new insights into the initiation of embryonic development and fertility control in mammals.**

Pre-implantation embryo development is dependent on stored maternal factors<sup>1,2</sup>. During meiosis in both sexes, germ-cell genomes are transcriptionally silenced. In the mouse, broad embryonic genome activation occurs at the late two-cell stage<sup>3,4</sup>. Hence, the oocyte-to-embryo transition depends on maternal transcripts and proteins that accumulate during oogenesis. Despite their many important functions, few mammalian maternal-effect genes have been identified<sup>9–12</sup>.

To identify novel oocyte-specific genes, we used subtractive hybridization and cDNA library screening to clone a novel gene called zygote arrest 1 (*Zar1*), which shows partial homology to a few egg-expressed expressed-sequence tags (AU023153, BB704019). The full-length *Zar1* cDNA encodes a protein of 361 amino acids (Fig. 1). RT-PCR (Fig. 2a) and northern-blot analyses (data not shown) identified a 1.4-kb *Zar1* transcript


only in the ovary. *In situ* hybridization analysis showed high levels of *Zar1* in growing oocytes of ovaries from wild-type mice (Fig. 3a,b) and from mice lacking the gene encoding growth differentiation factor 9 (*Gdf9*; ref. 13; Fig. 3c–f). Consistent with the expressed-sequence tag findings, we were able to amplify *Zar1* mRNA from wild-type oocytes and one-cell embryos. *Zar1* mRNA was much less abundant in two-cell embryos and was absent in embryos from four-cell through blastocyst stages and in *Zar1*<sup>−/−</sup> oocytes (Fig. 2b). Thus, *Zar1* mRNA is specifically synthesized in oocytes.

To clone the *Zar1* gene, we screened genomic libraries and characterized the recovered clones. *Zar1* and a related pseudogene (*Zar1-ps1*) contain four exons and map to Chromosome 5. *Zar1-ps1* contains a gap of 13 nucleotides in exon 1, which is predicted to result in a frameshift and protein truncation in exon 2. RT-PCR with *Zar1*-specific primers confirmed that *Zar1* was ovary-specific, but *Zar1-ps1* could not be amplified, establishing it as a pseudogene.

1	M A A L G D E V L D G Y V F P A C P P C S Y R P Y P A A T K G K G A A G G S W	ZAR1
2	H F P E A S T - - - - - F H P C P H - - - - - P Y F Q A T K - - - - - A G D G W	Zar1
3	G G R G R G C L P A S S P C S A G A A S L S F P G C G R L T A A S Y F D S Y Q R	ZAR1
4	R F G A R G C R P A P P S - - - - - - - - - F L P G Y R O L M A A E Y V D S H O P	Zar1
5	E R L M A L L A D A O V G P G L G P R A P R A G S C D V A V Q V S P R I D A A V Q C	ZAR1
6	A 57 A O L M A L L S R M G P - - - - - - - - - R S V S S R D A A V O V N P F R D A S V O C	Zar1
7	S L G R R T L Q R R A R D P E S P A G - P G A E G I T G G G S F S O O P S P R G	ZAR1
8	S L G R R T L C - - - - - - - - - P A G C F A S P D P R S G S C - - - - -	Zar1
9	L E Q G S F P C N G A F P R P H R P P R T V A V Y S P L A L E R I T A F L E G P G P	ZAR1
10	- - - - - C P R G H A G A G R S P R S N O T V A P F S S V T F C G L S S S L E V A G -	Zar1
11	A A G E O R S G A S D G E R G P P P R P L O G P E E G E V W T K A P P R P O S	ZAR1
12	- - - - - G S Q T P T K G E G S P A S S G T R E P E P R E V A A R K A V P O R S	Zar1
13	B D D G E A Q A Q A V R A S K W E Q F A D G P E L P P R E A O E G E A R P R S A L R	ZAR1
14	- - - - - G E D V O A A G O A G W E O C - - - - - P P F E D R N S V A A M O S E P G	Zar1
15	S P G O P P S A G R A R D G G D G R E A A V A G E B G P S P R S P E L G K E R L P	ZAR1
16	S E B P C P A A E M A O D P G D - - - S D A P R D Q A S P O S T Z Q D K E R L P	Zar1
17	F Q F L E Q K Y G Y Y H C K D C N I R W E S A Y V W C V O G T I N K V Y F K Q F C	ZAR1
18	F O F L E O K Y G Y Y H C K D C K I R W E S A Y V W C V O G T S K V Y F K Q F C	Zar1
19	F T C Q N K S Y N F Y R V E D I T C Q S C K O T R C I S C P V X L R H V D P K R P H	ZAR1
20	R V C E K S Y N P Y R V E D I T C Q S C K R T R C A C P V R L R H V D P K R P H	Zar1
21	R O D L C G R C K G K R L S C D S T F S F K Y I I	ZAR1
22	* * *	Zar1

**Fig. 1** Comparison of human *ZAR1* and mouse *Zar1* amino-acid sequences. Highest shared identity was observed in the C termini of these proteins. Asterisks denote the cysteine residues of an atypical PHD motif as predicted from ScanSite<sup>2</sup>.

<sup>1</sup>Department of Pathology, Baylor College of Medicine, One Baylor Plaza, Houston, Texas 77030, USA. <sup>2</sup>The Jackson Laboratory, Bar Harbor, Maine, USA. <sup>3</sup>Wyeth Research, Collegeville, Pennsylvania, USA. <sup>4</sup>Departments of Molecular and Cellular Biology and of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas, USA. <sup>5</sup>Present address: The Center for Transgenesis and Germ Cell Research, Department of Animal Biology, University of Pennsylvania, Kennett Square, Pennsylvania, USA. Correspondence should be addressed to M.M.M. (e-mail: mmatzuk@bcm.tmc.edu).



**Fig. 2** Expression analysis of zygote arrest 1 in mouse and human tissues. *a*, RT-PCR analysis of several mouse tissues showed a *Zar1*-specific 331-bp band only in ovary (ov). *b*, RT-PCR analysis of wild-type (wt) and *Zar1*<sup>-/-</sup> (null) oocytes and wild-type one-cell (1-c) through blastocyst- (blast) stage embryos detected *Zar1* mRNA in wild-type oocytes and one-cell and two-cell embryos. *c*, RT-PCR analysis of human tissues amplified a fragment of 530 bp. *Hprt* and *GAPD* were used as internal controls for the mouse and human RT-PCR, respectively, as described<sup>25,28</sup>. The function of *ZAR1* in the testis (te) is unknown. br, brain; lu, lung; he, heart; st, stomach; sp, spleen; li, liver; si, small intestine; ki, kidney; ut, uterus; co, colon; pr, prostate; pl, placenta; pa, pancreas; mu, muscle.

To identify the human *ZAR1* ortholog, we carried out BLAST searches and genomic-library screens. *ZAR1*, located on Chromosome 4 in a region of conserved synteny to that on mouse Chromosome 5 containing *Zar1*, spans 4.1 kb and contains four exons, which share 50%, 86%, 84% and 78% nucleotide identity with *Zar1* exons 1–4, respectively. No human pseudogene was found.


*ZAR1* is transcribed exclusively in ovary and testis (Fig. 2c). *ZAR1* mRNA is >1.3 kb and encodes a protein of 424 amino acids. *ZAR1* and *Zar1* proteins share 59% amino-acid identity (Fig. 1), and the C termini, encoded by exons 2–4, are highly conserved (91% shared identity). Although the public database lacks *ZAR1* homologs, an atypical PHD motif was discovered in the conserved C termini of *ZAR1* and *Zar1*. PHD sequences are typically characterized by a C<sub>4</sub>-H-C<sub>3</sub> (C-X<sub>2</sub>-C-X<sub>(9-21)</sub>-C-X<sub>(2-4)</sub>-C-X<sub>(4-5)</sub>-H-X<sub>2</sub>-C-X<sub>(12-46)</sub>-C-X<sub>2</sub>-C) zinc-binding amino-acid arrangement<sup>7</sup>. This motif is conserved in the *ZAR1* and *Zar1* C termini but is a C<sub>8</sub> pattern (C-X<sub>2</sub>-C-X<sub>13</sub>-C-X<sub>2</sub>-C-X<sub>4</sub>-C-X<sub>1</sub>-C-X<sub>17</sub>-C-X<sub>2</sub>-C). A C-to-H substitution is also present in the disease-associated PHD-containing protein ATRX<sup>14</sup>. Mutagenesis of the H to C in PHD-containing protein KAP-1 has a minimal effect, suggesting that these amino acids are functionally similar<sup>15</sup>. PHD domains are found in two major classes of proteins: (i) transcriptional activators, repressors or cofactors and (ii) subunits of complexes that modulate chromatin. Thus, *ZAR1* may be a transcriptional regulator, and the conserved *ZAR1* C terminus is probably functionally important.


**Fig. 3** Localization of *Zar1* in mouse ovaries. Expression of *Zar1* in wild-type (*a,b*) and *Gdf9*<sup>-/-</sup> (*c-f*; ref. 13) ovaries treated with PMSG was analyzed by *in situ* hybridization with a specific antisense probe. Bright-field (*a,c,e*) and corresponding dark-field (*b,d,f*) images of each ovary section are presented. Areas of panels *c* and *d* are shown at higher magnification in *e* and *f*. *Zar1* mRNA was detected at early primary follicle (type 3a) through antral follicle (type 8) stages, but not in primordial follicles (type 2). The follicle classification is based on Pedersen and Peters<sup>29</sup>.

To determine *Zar1* function, we generated *Zar1*-null (*Zar1*<sup>tm1Zuk</sup>) mutant mice (Fig. 4). Intercrossing F1 heterozygotes (Fig. 4b) yielded 232 F2 progeny (52 wild-type (22.5%), 119 heterozygous (*Zar1*<sup>+/-</sup>; 51.5%) and 60 homozygous-null (*Zar1*<sup>-/-</sup>) mice (26.0%)) from 32 litters. Thus, the mutated allele was transmitted with the expected mendelian frequency of 1:2:1. Northern-blot analysis showed a reduction in abundance of *Zar1* mRNA in *Zar1*<sup>+/+</sup> ovaries and was not able to detect the 1.4-kb *Zar1* mRNA in *Zar1*<sup>-/-</sup> ovaries (Fig. 4c), confirming that the *Zar1*<sup>tm1Zuk</sup> allele was null.

*Zar1*<sup>+/+</sup> and *Zar1*<sup>-/-</sup> male and female mice showed no gross or histological abnormalities. To test the fertility of *Zar1*<sup>+/+</sup> and *Zar1*<sup>-/-</sup> C57BL/6/129S6/SvEv hybrid mice, we mated them for six months. Consistent with ovary-specific expression of *Zar1*, *Zar1*<sup>-/-</sup> males were fertile (7.4 ± 0.4 pups per litter). Mating of 14 *Zar1*<sup>+/+</sup> females with *Zar1*<sup>+/+</sup> males resulted in 80 litters (0.95 litters per month per mouse; 7.9 ± 0.3 pups per litter), similar to wild-type matings (8.4 ± 0.2 pups per litter; ref. 16). In contrast, breeding of 20 *Zar1*<sup>-/-</sup> females yielded no offspring over six months. Likewise, ten *Zar1*<sup>-/-</sup> 129S6/SvEv inbred females bred over six months were also infertile. Thus, *Zar1* is essential for female fertility.

To further define *Zar1* function, we evaluated expression and subcellular localization of *Zar1* in oocytes and early embryos. Consistent with the RT-PCR data, we identified a 45-kDa *Zar1*-specific band only in mouse ovary by western-blot analysis (Fig. 5a). *Zar1* localized predominantly to the cytoplasm of oocytes of wild-type (Fig. 5b,c) and *Gdf9*<sup>-/-</sup> ovaries (Fig. 5d) and was present from primary through antral follicle stages (Fig. 5e). *Zar1* was distributed diffusely throughout the cytoplasm of fully grown oocytes isolated







**Fig. 4** Targeting strategy of *Zar1* and Southern blot and northern blot analyses of F2 offspring. **a**, A targeting vector was constructed by replacing exon 1 (the largest exon, which contains the initiation ATG) and part of intron 1 with a *PgkHPRT* expression cassette. The *MC1tk* expression cassette was used for negative selection. Targeted ES cell clones containing a wild-type (wt) allele, a pseudogene allele (*Zar1-ps1*) and a mutated (mut) allele were confirmed by Southern blot analysis<sup>22</sup> and injected into blastocysts to produce chimeric male mice<sup>22,23</sup>, which were bred to produce F1 *Zar1<sup>+/+</sup>* offspring. **b**, Southern blot analysis of genomic DNA derived from seven offspring of one litter from *Zar1<sup>+/+</sup>* intercrosses. Similar numbers of male and female homozygotes were born. Southern blot analysis with an exon 1 probe detected only the pseudogene in DNA derived from *Zar1<sup>+/+</sup>* mice. **c**, Northern blot analysis of ovarian mRNA from wild-type, *Zar1<sup>+/+</sup>* and *Zar1<sup>-/-</sup>* females with the full-length *Zar1* cDNA. On longer exposure, a smaller transcript of unknown relevance was observed in *Zar1<sup>-/-</sup>* ovaries. The expression level of the 1.4-kb *Zar1* mRNA in wild-type mice was approximately twice the levels present in *Zar1<sup>-/-</sup>* ovaries. **d**, *Gapd* was used as a control for equivalent loading on the northern blot.

from *Zar1<sup>+/+</sup>* mice (Fig. 5*f*) but was not present in ovaries (Fig. 5*e*) and oocytes (Fig. 5*g*) from *Zar1<sup>-/-</sup>* females. *Zar1* was also detected after resumption of meiosis through progression to metaphase II (Fig. 5*h,i*). *Zar1* persisted in one-cell embryos (Fig. 5*j*) but was markedly less abundant in two-cell embryos (Fig. 5*k*). Thus, *Zar1* could function in growing oocytes through formation of two-cell embryos. The rapid disappearance of *Zar1* at the two-cell stage, however, suggests a critical role in the oocyte-to-embryo transition.

To determine the cause of the infertility in female *Zar1<sup>-/-</sup>* mice, we examined ovarian histology. Ovaries from *Zar1<sup>-/-</sup>* females

(Fig. 5*e*) were indistinguishable from those of control females. All stages of follicle development and corpora lutea (indicative of ovulation) were evident in ovaries of *Zar1<sup>-/-</sup>* females. Moreover, superovulation resulted in similar numbers of oocytes from *Zar1<sup>+/+</sup>* ( $31.6 \pm 4.7$ ;  $n = 8$ ) and *Zar1<sup>-/-</sup>* ( $34.3 \pm 4.1$ ;  $n = 14$ ) females. Most *Zar1<sup>+/+</sup>* ( $74.4 \pm 5.5\%$ ;  $n = 156$ ) and *Zar1<sup>-/-</sup>* oocytes ( $62.9 \pm 4.3\%$ ;  $n = 137$ ) resumed meiosis and progressed to metaphase II during a 17-h culture. Like heterozygous controls ( $92.9 \pm 2.1\%$ ), *Zar1<sup>-/-</sup>* oocytes formed two pronuclei within 8 h after insemination ( $82.4 \pm 7.5\%$ ). Whereas the first cleavage





**Fig. 6** Development of embryos derived from *Zar1<sup>+/−</sup>* and *Zar1<sup>−/−</sup>* mice. Adult *Zar1<sup>+/−</sup>* (*a*) and *Zar1<sup>−/−</sup>* (*b*) females were mated with stud males. Eggs and embryos were collected from the oviduct and uterus on d 3.5 after vaginal plug. Whereas all zygotes ( $n = 41$ ) from *Zar1<sup>+/−</sup>* female mice ( $n = 6$ ) progressed to the blastocyst stage (*a*), most zygotes ( $n = 19$ ) from *Zar1<sup>−/−</sup>* mice ( $n = 9$ ) remained at the one-cell stage, and many degenerating embryos were detected (*b*). Oocytes from *Zar1<sup>+/−</sup>* and *Zar1<sup>−/−</sup>* mice (*c*) were matured and fertilized *in vitro*. 24 h after fertilization, the arrested zygotes from *Zar1<sup>−/−</sup>* females were labeled with antibody against  $\beta$ -tubulin and propidium iodide to assess microtubule and chromatin configurations, respectively. Decondensed chromatin (red) was evident in maternal and paternal pronuclei. The microtubules are shown in green. In a second experiment, the fertilized zygotes were placed in medium with BrdU 8 h after fertilization and cultured overnight (*d*). Immunofluorescence analysis showed BrdU incorporation in both pronuclei (bright orange) of an arrested zygote from a *Zar1<sup>−/−</sup>* female, indicative of entry into S phase. *e*, Early embryos from inseminated *Zar1* null eggs underwent embryonic genome activation. TRC synthesis was detected in two-cell-stage embryos from wild-type control (ctrl) and *Zar1<sup>−/−</sup>* females. Culture with  $\alpha$ -amanitin ( $\alpha$ -amanitin,  $11 \mu\text{g ml}^{-1}$ ), an inhibitor of RNA polymerase II, prevented TRC synthesis. The TRC experiments were performed as described<sup>8</sup> using 15 embryos per lane.

occurred in most *in vivo* (89.3%) and *in vitro* ( $86.5 \pm 1.4\%$ ) fertilized embryos from *Zar1<sup>+/−</sup>* females, we observed two-cell embryos (some of which appeared fragmented) in only  $19.1 \pm 9.1\%$  (*in vitro*) and  $20.8 \pm 1.5\%$  (*in vivo*) of embryos from *Zar1<sup>−/−</sup>* females. 100% of embryos isolated from uteri of *Zar1<sup>+/−</sup>* females developed to blastocysts by day 3.5, and most cultured control embryos progressed to morula and blastocyst stages ( $82.1 \pm 1.5\%$ ), but we observed only fragmented one-cell embryos and a single two-cell embryo in *Zar1<sup>−/−</sup>* females (Fig. 6*a,b*). Therefore, an arrest at the zygote and two-cell stages accounts for the infertility of *Zar1<sup>−/−</sup>* females.

Additional analysis of the embryonic block showed that *Zar1* null zygotes progressed through G1 and successfully entered S phase. Both pronuclei had decondensed chromatin and incorporation of 5-bromo-2-deoxyuridine (BrdU; Fig. 6*c,d*). The microtubule network showed an interphase configuration with no assembled spindle apparatus. *In vitro* fertilized oocytes were treated with colcemid, which depolymerized microtubules and arrested all zygotes from *Zar1<sup>+/−</sup>* females at M phase. Only a few *Zar1* null zygotes were similarly arrested, but this number corresponded to the small percentage of *Zar1* null embryos that entered M phase and became two-cell embryos, indicating that most arrested earlier at the S or G2 stages. Thus, the maternal and paternal genomes remained separate in discrete pronuclei, and the two haploid genomes did not unite, indicating that the fertilization had not been completed.

To further define the block in the *Zar1* null embryos, we analyzed the synthesis of a group of proteins called the transcription-requiring complex (TRC), markers of embryonic genomic activation<sup>8</sup>. Although TRC proteins were detected in the limited number of *Zar1* null embryos that reached the two-cell stage, their TRC expression levels were 15% of those of the control embryos, suggesting that there are defects in embryonic genome activation (Fig. 6*e*). The precise mechanisms by which *Zar1* directs the oocyte-to-embryo transition have yet to be determined.

The decrease in *Zar1* expression in normal two-cell embryos correlates with the usual rapid degradation of maternal transcripts after fertilization<sup>17</sup>. Developmental processes ongoing at this time include completion of the meiotic-to-mitotic cell-cycle transition and activation of the embryonic genome<sup>1–4</sup>.

Notably, inhibition of embryonic transcription does not prevent the first mitotic division but arrests embryos beyond the two-cell stage<sup>17</sup>. Of the other maternal-effect genes<sup>9–12</sup>, only *Mater* (maternal antigen that embryos require) is expressed exclusively in oocytes and early pre-implantation embryos. Compared with *Zar1* null embryos, *Mater* null embryos block at the two-cell stage and have higher levels of genome activation. The predominant one-cell-stage arrest of fertilized eggs from *Zar1<sup>−/−</sup>* females suggests that this maternal factor functions before embryonic genome activation. Although both *Mater* (53%) and *Zar1* (59%) share low identity with their human orthologs<sup>18</sup>, these human orthologs probably have conserved functions in early embryogenesis and fertility. Identification of proteins that interact with *Zar1* may provide insights into the roles of this maternal protein in regulating the essential transition from oocyte to embryo. This study presents the first identification and characterization of zygote arrest 1, a gene expressed during oocyte development, the function of which is key for the initiation of embryogenesis.

## Methods

**mRNA expression analysis.** We obtained total RNA from mouse tissues or embryos using the RNA STAT-60 method (Leedo Medical Laboratories). We carried out *in situ* hybridization with a *Zar1*-specific probe as described<sup>19,20</sup>. We carried out RT-PCR analysis of mouse and human cDNAs (primer sequences are available upon request).

**Mouse ovary cDNA library and genomic library screening.** We used a *Zar1* cDNA probe (corresponding to nucleotides 896–1,220 of the full-length *Zar1* cDNA) to screen a wild-type mouse ovary cDNA library. We used the full length 1,259-nt *Zar1* cDNA, which contains an open reading frame from nt 28–1,110, to screen 12956/SvEv mouse genomic  $\lambda$  FixII phage and human genomic DNA libraries (Stratagene). We also used *Zar1*-specific primers to screen a 129X1/SvJ BAC library (Genome Systems). We hybridized filters as described<sup>21</sup>.

**ES-cell manipulation and Southern blot analysis.** We electroporated the linearized *Zar1* targeting vector into the HPRT-negative AB2.2 ES-cell line, selected clones in hypoxanthine, aminopteridine and thymidine and 1-(2'-deoxy-2'-fluoro- $\beta$ -D-arabinofuranosyl)-5-iodouracil and screened DNA from the clones by Southern blot analysis. We found that 5 of 171 (3%) of the ES cell clones analyzed were targeted at the *Zar1* locus. ES cell line *Zar1*-140-G11 was injected into blastocysts to produce chimeric male mice

that were fertile and transmitted the mutated *Zar1* allele (*Zar1<sup>tm1</sup>Zuk*, herein called *Zar1<sup>-/-</sup>*) to F1 progeny as described<sup>22,23</sup>.

**Superovulation, mating and *in vitro* embryo culture.** We injected 25-d-old *Zar1<sup>+/+</sup>* and *Zar1<sup>-/-</sup>* female mice with pregnant mare serum gonadotropin (PMSG; intraperitoneal injection of 5 IU per mouse) and gave them human chorionic gonadotropin (intraperitoneal injection of 5 IU per mouse) 48 h later. Mice were then caged overnight with (C57BL/6) × 129S6/SvEv) F1 stud males. The following morning, we recovered eggs and embryos in M2 medium, counted them and cultured them *in vitro* up to 4 d in M16 medium (Sigma). Alternatively, adult mutant females were mated to stud males, uteri and oviducts were flushed on d 1.5, 2.5 or 3.5, and embryos were collected and cultured in M16 medium.

**In vitro oocyte maturation and fertilization.** We injected sexually mature *Zar1<sup>+/+</sup>* and *Zar1<sup>-/-</sup>* female mice with 5 IU of PMSG to stimulate pre-ovulatory follicle development. We isolated cumulus-enclosed oocyte complexes 48 h later and cultured them for 17 h in minimal essential medium with 5% serum. We subsequently removed the surrounding somatic cells and examined the oocytes to determine the progression of meiosis. Mature MII-stage eggs were inseminated *in vitro* with sperm from wild-type (C57BL/6J × SJL/J) F1 mice<sup>24</sup>. We assessed development of zygotes and two-cell-stage embryos 6 and 24 h after fertilization, respectively. We evaluated blastocyst formation on d 5.

**Production of polyclonal antibodies against *Zar1* and immunostaining.** We subcloned a partial mouse *Zar1* cDNA (nt 178–1,083 corresponding to amino acids 51–352) into pET23b vector (Novagen) and injected chimeric recombinant *Zar1* protein (with a T7 tag at the N terminus and His tag at the C terminus) into goats to produce polyclonal antibodies (CoCalico Biologicals). We carried out western-blot analysis and immunostaining as described<sup>25</sup> using primary antibody (diluted at 1:1,000). For western-blot analysis, we used secondary antibody against goat conjugated with horseradish peroxidase (Boehringer Mannheim; diluted at 1:2,000) and ECL Western Blotting Detection Reagents (Amersham Biosciences). For immunostaining, we carried out incubation with secondary antibody and visualization of positive cells using the New Fuchsin kit (BioGenex). We used pre-immune serum in control sections.

**Immunofluorescence.** We carried out immunofluorescence analysis of oocytes and embryos as described<sup>25</sup>. We carried out reactions with the goat *Zar1* antisera (diluted at 1:1,000 in block solution) for 1 h and then exposed samples to 3 µg ml<sup>-1</sup> of antibody against rabbit IgG conjugated with fluorescein isothiocyanate (Jackson Immuno Research Laboratories) for 45 min. We labeled DNA with propidium iodide (10 µg ml<sup>-1</sup> for 10 min). We evaluated negative controls with pre-immune serum.

We evaluated fertilized zygotes that had not undergone the first mitotic division by 24 h after fertilization to determine chromatin and microtubule configurations. The zygotes were fixed, permeabilized and blocked. We carried out all subsequent steps, including rinses, at 37 °C in block solution. We labeled microtubules with antibody against β-tubulin (3.8 µg ml<sup>-1</sup> for 1 h) and secondary antibody against mouse conjugated with fluorescein isothiocyanate (1.3 µg ml<sup>-1</sup> for 45 min) and labeled DNA with propidium iodide as above. We detected fluorescence using a confocal microscope.

**DNA synthesis.** Fully-grown oocytes from *Zar1<sup>+/+</sup>* and *Zar1<sup>-/-</sup>* mice were *in vitro* matured and fertilized as above. Approximately 8 h after fertilization, we transferred the zygotes that formed male and female pronuclei to medium supplemented with 50 µM BrdU for overnight culture. 24 h after fertilization, embryos were fixed and processed to assess BrdU incorporation<sup>26</sup>. We detected fluorescence using a confocal microscope.

**Statistical analysis.** We calculated statistical significance by one-way ANOVA. Data are expressed as mean ± s.e.m.

**URL.** ScanSite<sup>27</sup> is available at <http://scansite.mit.edu>.

**GenBank accession numbers.** *Zar1* cDNA, AY191415; *Zar1* gene, AY193889; *ZARI* cDNA, AY191416; *ZARI* gene, AY193890.

## Acknowledgments

We thank M. Berry, R. Burgess, K. Burns, T. Gridley, G. Kopf and T. Kumar for critical review of the manuscript, S. Baker for aid in manuscript formatting and C. Brown, K. Burns, L. Chen, L. Erdos, M. O'Brien, P. Wang and C. Yan for technical assistance. These studies were supported in part by a sponsored research grant from Wyeth Research and US National Institutes of Health grants (to M.M.M. and J.J.E.). X. Wu was supported in part by a post-doctoral fellowship from the Lalor Foundation.

## Competing interests statement

The authors declare competing financial interests: see the *Nature Genetics* website (<http://www.nature.com/naturegenetics>) for details.

Received 20 August; accepted 9 December 2002.

1. Latham, K.E. Mechanisms and control of embryonic genome activation in mammalian embryos. *Int. Rev. Cytol.* **193**, 71–124 (1999).
2. Latham, K.E. & Schultz, R.M. Embryonic genome activation. *Front. Biosci.* **6**, 748–759 (2001).
3. Schultz, R.M. Regulation of zygotic gene activation in the mouse. *Bioessays* **15**, 531–538 (1993).
4. Aoki, F., Worrad, D.M. & Schultz, R.M. Regulation of transcriptional activity during the first and second cell cycles in the pre-implantation mouse embryo. *Dev. Biol.* **181**, 296–307 (1997).
5. Matzuk, M.M., Burns, K., Viveiros, M.M. & Eppig, J. Intercellular communication in the mammalian ovary: oocytes carry the conversation. *Science* **296**, 2178–2180 (2002).
6. Matzuk, M.M. & Lamb, J.D. Genetic dissection of mammalian fertility pathways. *Nat. Med.* **8**, S41–S49 (2002).
7. Aasland, R., Gibson, T.J. & Stewart, A.F. The PHD finger: implications for chromatin-mediated transcriptional regulation. *Trends Biochem. Sci.* **20**, 56–59 (1995).
8. Conover, J.C., Temeles, G.L., Zimmermann, J.W., Burke, B. & Schultz, R.M. Stage-specific expression of a family of proteins that are major products of zygotic gene activation in the mouse embryo. *Dev. Biol.* **144**, 392–404 (1991).
9. Tong, Z.B. et al. Mater, a maternal effect gene required for early embryonic development in mice. *Nat. Genet.* **26**, 267–268 (2000).
10. Howell, C.Y. et al. Genomic imprinting disrupted by a maternal-effect mutation in the *Dnmt1* gene. *Cell* **104**, 829–838 (2001).
11. Polla, T.A. et al. Tumour susceptibility and spontaneous mutation in mice deficient in *Mlh1*, *Pms1* and *Pms2* DNA mismatch repair. *Nat. Genet.* **18**, 276–279 (1998).
12. Christians, E., Davis, A.A., Thomas, S.D. & Benjamin, I.J. Maternal effect of *Hsf1* on reproductive success. *Nature* **407**, 693–694 (2000).
13. Dong, J. et al. Growth differentiation factor 9 is required during early ovarian folliculogenesis. *Nature* **383**, 531–535 (1996).
14. Gibbons, R.J. et al. Mutations in transcriptional regulator ATRX establish the functional significance of a PHD-like domain. *Nat. Genet.* **17**, 146–148 (1997).
15. Capili, A.D., Schultz, D.C., Rauscher, I.F. & Borden, K.L. Solution structure of the PHD domain from the KAP-1 corepressor: structural determinants for PHD, RING and LIM zinc-binding domains. *EMBO J.* **20**, 165–177 (2001).
16. Kumar, T.R. et al. Reproductive defects in γ-glutamyl transpeptidase-deficient mice. *Endocrinology* **141**, 4270–4277 (2000).
17. Flach, G., Johnson, M.H., Braude, P.R., Taylor, R.A. & Bolton, V.N. The transition from maternal to embryonic control in the two-cell mouse embryo. *EMBO J.* **1**, 681–686 (1982).
18. Tong, Z.B., Bondy, C.A., Zhou, J. & Nelson, L.M. A human homologue of mouse Mater, a maternal-effect gene essential for early embryonic development. *Hum. Reprod.* **17**, 903–911 (2002).
19. Albrecht, U., Eichle, G., Helms, J.A. & Lu, H.C. Visualization of gene expression patterns by *in situ* hybridization. In *Molecular and Cellular Methods in Developmental Toxicology* (ed. Daston, G.P.) 23–48 (CRC Press, Boca Raton, Florida, 1997).
20. Elvin, J.A., Yan, C., Wang, P., Nishimori, K. & Matzuk, M.M. Molecular characterization of the follicle defects in the growth differentiation factor 9-deficient ovary. *Mol. Endocrinol.* **13**, 1018–1034 (1999).
21. Matzuk, M.M. & Bradley, A. Structure of the mouse activin receptor type II gene. *Biochem. Biophys. Res. Commun.* **185**, 404–413 (1992).
22. Matzuk, M.M., Finegold, M.J., Su, J.-G.J., Hsueh, A.J.W. & Bradley, A. α-Inhibin is a tumor-suppressor gene with gonadal specificity in mice. *Nature* **360**, 313–319 (1992).
23. Bradley, A. Production and analysis of chimeric mice-teratocarcinomas and embryonic stem cells: a practical approach. In *Production and Analysis of Chimeric Mice* (ed. Robinson, E.J.) 113–151 (Oxford, London, 1987).
24. Eppig, J.J. Mouse oocyte maturation, fertilization, and pre-implantation development *in vitro*. In *A Comparative Methods Approach to the Study of Oocytes and Embryos* (ed. Richter, J.D.) 3–9 (Oxford University Press, Oxford, 1999).
25. Yan, W. et al. Identification of *Gaz1*, an evolutionarily conserved gene expressed exclusively in germ cells and encoding a protein with four ankyrin repeats, a sterile-alpha motif, and a basic leucine zipper. *Mol. Endocrinol.* **16**, 1168–1184 (2002).
26. Ferreira, J. & Carmo-Fonseca, M. Genome replication in early mouse embryos follows a defined temporal and spatial order. *J. Cell. Sci.* **110**, 889–897 (1997).
27. Yaffe, M.B. et al. A motif-based profile scanning approach for genome-wide prediction of signaling pathways. *Nat. Biotechnol.* **19**, 348–353 (2001).
28. Elvin, J.A., Clark, A.T., Wang, P., Wolfman, N.M. & Matzuk, M.M. Paracrine actions of growth differentiation factor 9 in the mammalian ovary. *Mol. Endocrinol.* **13**, 1035–1048 (1999).
29. Pedersen, T. & Peters, H. Proposal for a classification of oocytes and follicles in the mouse ovary. *J. Reprod. Fertil.* **17**, 555–557 (1968).